{"gene":"CDK4","run_date":"2026-04-28T17:28:52","timeline":{"discoveries":[{"year":1993,"finding":"p16 (INK4a) binds directly to CDK4 and inhibits the catalytic activity of CDK4/cyclin D complexes, acting in a regulatory feedback circuit with CDK4, D-type cyclins, and retinoblastoma protein.","method":"Biochemical binding assays, kinase inhibition assays, cDNA isolation","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro kinase inhibition assay, foundational discovery replicated extensively","pmids":["8259215"],"is_preprint":false},{"year":1993,"finding":"CDK4 in complex with D-type cyclins phosphorylates the retinoblastoma protein (pRb) at sites identical to those phosphorylated in human T cells; only D-type cyclins activate CDK4 enzyme activity; cyclin D2/D3 (but not D1) bind pRb directly; CDK4/cyclin D complexes phosphorylate pRb and release E2F-1.","method":"Baculovirus/Sf9 reconstitution, in vitro kinase assay, co-immunoprecipitation, pRb fusion protein phosphorylation","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — reconstituted in vitro with multiple orthogonal methods, foundational study","pmids":["8449399"],"is_preprint":false},{"year":1993,"finding":"In SV40-transformed cells, CDK4 dissociates from cyclin D, PCNA, and p21 and instead associates exclusively with a 16 kDa protein (p16), demonstrating subunit rearrangement of CDK4 complexes is associated with cellular transformation.","method":"Co-immunoprecipitation, biochemical fractionation of normal vs. transformed fibroblasts","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 2 — reciprocal co-IP, replicated across multiple transformation models","pmids":["8101826"],"is_preprint":false},{"year":1994,"finding":"CDK4/cyclin D complexes require phosphorylation on Thr-172 for enzymatic activation; this step is catalyzed by CAK (cdk-activating kinase, p39MO15/cyclin H complex), which can phosphorylate and activate both cdk2 and cdk4 in their respective cyclin complexes.","method":"In vitro kinase assay, immune-depletion, baculovirus reconstitution with p39MO15 and cyclin H","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — in vitro reconstitution with activating phosphorylation assay and immune-depletion validation","pmids":["7935441"],"is_preprint":false},{"year":1994,"finding":"p21(CIP), p27(KIP), and p57(KIP2) promote the assembly of CDK4 with D-type cyclins; at low concentrations p21 promotes active CDK4/cyclin D complex formation, and most cellular CDK4/cyclin D kinase activity co-associates with p21; CIP/KIP proteins also target CDK4 and cyclin D1 to the nucleus.","method":"In vitro assembly assays, kinetic analyses (K_a, K_off measurements), immunodepletion, subcellular fractionation","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — quantitative in vitro assembly kinetics plus in vivo immunodepletion, multiple orthogonal methods","pmids":["9106657"],"is_preprint":false},{"year":1994,"finding":"p15INK4B, a new member of the p16 family induced ~30-fold by TGF-β in human keratinocytes, inhibits CDK4 and CDK6, identifying it as a potential effector of TGF-β-mediated G1 cell cycle arrest.","method":"cDNA isolation, TGF-β induction assay, CDK4/6 kinase inhibition assay","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct kinase inhibition demonstrated, TGF-β induction linked mechanistically","pmids":["8078588"],"is_preprint":false},{"year":1994,"finding":"CDK6 (PLSTIRE gene product) is activated by D-type cyclins and phosphorylates pRb during mid-G1, analogous to CDK4.","method":"Sf9 baculovirus co-expression, in vitro kinase assay, co-immunoprecipitation","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — reconstituted activity in insect cells, pRb phosphorylation confirmed","pmids":["8114739"],"is_preprint":false},{"year":1994,"finding":"p18 (INK4C) interacts strongly with CDK6 and weakly with CDK4, inhibits cyclin D-CDK6 kinase activity, and forms binary (not ternary) complexes with CDK4/CDK6, competing with cyclin binding; growth suppression by p18 correlates with wild-type pRb function.","method":"Yeast two-hybrid, in vitro binding, kinase inhibition assay, growth suppression in NIH 3T3 cells","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1 — multiple orthogonal methods including in vitro kinase assay and genetic growth suppression assay","pmids":["8001816"],"is_preprint":false},{"year":1994,"finding":"A 15-kDa CDK-binding protein (p15cdk-BP) specifically binds CDK4/cyclin D and CDK5, but not CDC2 or CDK2, identifying a distinct CDK4-selective binding partner.","method":"Affinity chromatography (p15cdk-BP-Sepharose), anti-CDK antibody Western blotting, phosphopeptide mapping","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 — affinity pulldown with multiple CDK specificity controls","pmids":["8175758"],"is_preprint":false},{"year":1995,"finding":"A CDK4 R24C point mutation (arginine-to-cysteine at residue 24) found in human melanoma prevents binding of p16INK4a (but not p21 or p27KIP1), rendering CDK4 insensitive to this tumor suppressor; the mutant peptide is recognized as a tumor-specific antigen by cytolytic T lymphocytes.","method":"Mutant CDK4 sequencing from melanoma tissue, p16/p21/p27 binding assay, CTL recognition assay","journal":"Science","confidence":"High","confidence_rationale":"Tier 2 — direct binding assay with multiple inhibitors, confirmed in tumor tissue and CTL assay","pmids":["7652577"],"is_preprint":false},{"year":1995,"finding":"Mouse p19 (INK4D) and p18 (INK4C) specifically inhibit CDK4 and CDK6 kinase activities but not CDK2, CDC2; they bind CDK4/CDK6 directly (in or out of cyclin D complexes) and can displace cyclin D from CDK4/6 in vivo, inducing G1 arrest.","method":"In vitro kinase inhibition assay, co-immunoprecipitation, retroviral overexpression, cell cycle analysis","journal":"Molecular and cellular biology","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro kinase inhibition plus in vivo genetic assay","pmids":["7739547"],"is_preprint":false},{"year":1996,"finding":"p19INK4D is a specific inhibitor of CDK4 and CDK6; it interacts with both kinases (independently of cyclins) and inhibits their activity; interaction with CDK4/CDK6 is hindered by the cyclin subunit, and binary cyclin D–p19 or cyclin D–CDK6 complexes are mutually exclusive, suggesting INK4 proteins and D cyclins compete for CDK4/6 binding.","method":"Yeast two-hybrid, co-immunoprecipitation, kinase inhibition assay, chromosome mapping","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 1-2 — multiple binding/inhibition assays, competition demonstrated biochemically","pmids":["8741839"],"is_preprint":false},{"year":1996,"finding":"During myogenic differentiation, p18INK4C protein increases 50-fold and sequentially associates first with CDK6 then with CDK4, with all CDK6 and half of CDK4 complexed with p18 in terminally differentiated muscle; CDK4 kinase activity decreases during differentiation, supporting p18 as critical for maintaining permanent cell cycle arrest in muscle.","method":"Co-immunoprecipitation, Western blot, kinase activity assay in C2C12 cells and adult mouse muscle","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 — kinase assay plus co-IP across differentiation time course in two biological contexts","pmids":["8898364"],"is_preprint":false},{"year":1996,"finding":"Random mutagenesis of p16INK4a reveals that multiple residues throughout the entire gene are important for binding to CDK4, with no single mutational hot spot; mutations reducing binding also severely affect kinase-inhibitory activity.","method":"Random mutagenesis, yeast two-hybrid binding assay, kinase inhibition assay","journal":"Biochemical and biophysical research communications","confidence":"Medium","confidence_rationale":"Tier 2 — systematic mutagenesis screen with binding and functional assays","pmids":["8573142"],"is_preprint":false},{"year":1996,"finding":"Germline CDK4 R24C (and R24H) mutations in the p16INK4a-binding domain cause familial melanoma susceptibility.","method":"Germline mutation sequencing in familial melanoma kindreds","journal":"Nature genetics","confidence":"High","confidence_rationale":"Tier 2 — genetic epistasis confirmed in multiple melanoma families, functionally linked to p16 binding domain","pmids":["8528263"],"is_preprint":false},{"year":1997,"finding":"ARF (p19ARF) binds to MDM2 and promotes its degradation, stabilizing p53; deletion of the INK4a-ARF locus simultaneously impairs both the p16INK4a-cyclin D/CDK4-Rb and ARF-MDM2-p53 tumor suppression pathways.","method":"Co-immunoprecipitation, MDM2 degradation assay, G1 arrest rescue experiment","journal":"Cell","confidence":"High","confidence_rationale":"Tier 2 — mechanistic dissection of two tumor suppressor pathways with biochemical and cell-based assays","pmids":["9529249"],"is_preprint":false},{"year":1999,"finding":"CDK4 T172 phosphorylation in the T-loop is a critical activating modification; the novel CDK4-binding protein p34(SEI-1) antagonizes p16INK4a by rendering cyclin D1-CDK4 resistant to p16INK4a inhibition, and SEI-1 expression is induced by serum stimulation, facilitating cyclin D-CDK complex formation.","method":"In vitro kinase assay, p16 competition binding assay, serum induction experiment, ectopic expression in fibroblasts","journal":"Genes & development","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical reconstitution of p16 resistance plus cellular proliferation assay","pmids":["10580009"],"is_preprint":false},{"year":1999,"finding":"Sequential CDK4/6-dependent phosphorylation of the Rb C-terminal region initiates intramolecular interactions that displace histone deacetylase from the Rb pocket, blocking active transcriptional repression; subsequent CDK2-mediated pocket phosphorylation disrupts pocket structure and releases E2F, providing a molecular basis for ordered Rb inactivation during G1.","method":"In vitro phosphorylation assays, mutant Rb constructs, co-immunoprecipitation, HDAC binding assays","journal":"Cell","confidence":"High","confidence_rationale":"Tier 1 — reconstitution with defined mutants, multiple orthogonal assays, mechanistically detailed","pmids":["10499802"],"is_preprint":false},{"year":2000,"finding":"c-MYC transcriptionally activates CDK4 via four conserved MYC binding sites in the CDK4 promoter; c-MYC-deficient RAT1 cells show delayed cell cycle progression associated with defective CDK4 induction, and ectopic CDK4 expression partially rescues this growth defect.","method":"Serial analysis of gene expression (SAGE), promoter binding/transcription assay, c-MYC-deficient cell rescue experiment","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — promoter binding demonstrated, genetic rescue with ectopic CDK4 confirms pathway placement","pmids":["10688915"],"is_preprint":false},{"year":2001,"finding":"Knock-in mice expressing the CDK4 R24C allele (insensitive to INK4 inhibition) are highly susceptible to melanoma development; these tumors lack p19ARF/p53 mutations, indicating the p16INK4a/CDK4/Rb pathway is specifically involved in melanoma. Deletion of p18INK4C (but not p15INK4B) confers additional proliferative advantage, establishing a functional hierarchy of INK4 proteins on CDK4 in melanocytes.","method":"Knock-in mouse model, carcinogen treatment, tumor sequencing, genetic epistasis with INK4 knockouts","journal":"PNAS","confidence":"High","confidence_rationale":"Tier 2 — in vivo genetic epistasis with multiple INK4 knockouts, pathway-specific tumor suppressor dissection","pmids":["11606789"],"is_preprint":false},{"year":2006,"finding":"Single-particle electron microscopy of a reconstituted Hsp90-Cdc37-Cdk4 complex defines its 3D structure and stoichiometry; Cdc37 acts as a scaffold simultaneously binding Cdk4 and Hsp90, and conformational changes in Cdk4 are coupled to the Hsp90 ATPase cycle.","method":"Reconstitution and purification of ternary complex, single-particle EM, stoichiometry determination, comparison with Hsp90 crystal structure","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — structural determination with reconstituted complex and mechanistic coupling analysis","pmids":["16949366"],"is_preprint":false},{"year":2006,"finding":"Combined loss of Cdk2 and Cdk4 in mice causes embryonic lethality (~E15) with heart defects, progressive decline in Rb phosphorylation, reduced E2F-target gene expression, and premature senescence in MEFs; HPV-E7 inactivation of Rb rescues these defects, demonstrating Cdk2 and Cdk4 cooperate to phosphorylate Rb in vivo and couple G1/S transition to mitosis via E2F.","method":"Double knockout mice, Rb phosphorylation assay, E2F target gene expression, HPV-E7 rescue, p27 knockout epistasis","journal":"Developmental cell","confidence":"High","confidence_rationale":"Tier 2 — genetic double knockout with multiple epistasis rescue experiments","pmids":["16678773"],"is_preprint":false},{"year":2006,"finding":"T-loop phosphorylation of CDK4 (but not CDK6) at Thr172 is a determining target for cell cycle control by extracellular factors; CDK4's subcellular location and association with D-type cyclins are regulated by mitogenic/antimitogenic signals.","method":"Biochemical analysis of CDK4 T172 phosphorylation in response to extracellular signals, subcellular fractionation, comparison with CDK6","journal":"Cell division","confidence":"Medium","confidence_rationale":"Tier 2 — phosphorylation-specific analysis with extracellular signal linkage, single lab review synthesis","pmids":["17092340"],"is_preprint":false},{"year":2009,"finding":"The CDK4-pRB-E2F1 pathway controls insulin secretion in pancreatic β-cells by regulating expression of Kir6.2 (a K-ATP channel component); glucose activates CDK4 via the insulin/GSK-3β pathway, leading to E2F1 activation and increased Kir6.2 expression; CDK4 inhibition or E2F1 knockout impairs insulin secretion and causes glucose intolerance in mice.","method":"Chromatin immunoprecipitation from tissues, CDK4 inhibitor treatment, E2f1−/− mouse phenotype, Kir6.2 rescue experiment","journal":"Nature cell biology","confidence":"High","confidence_rationale":"Tier 2 — ChIP from tissues, genetic knockout, pharmacologic inhibition, and rescue assay","pmids":["19597485"],"is_preprint":false},{"year":2010,"finding":"STAT1 directly interacts with the cyclin D1/CDK4 complex; IFN-γ activates STAT1 (via Ser727 phosphorylation), which interacts with cyclin D1 to promote its proteasomal degradation, reducing Rb phosphorylation and inducing G1 arrest independently of STAT1 transcriptional activity.","method":"Co-immunoprecipitation, STAT1 point mutant analysis, proteasome inhibitor treatment, STAT1-deficient cell comparison","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 — co-IP plus genetic (STAT1-deficient cells) and pharmacologic (proteasome inhibitor) validation","pmids":["21084836"],"is_preprint":false},{"year":2013,"finding":"Cdk7 is a Cdk4- and Cdk6-activating kinase in human cells, required to maintain (not just establish) Cdk4 activity; Cdk7 activating phosphorylation rises concurrently with Cdk4 activating phosphorylation as cells exit quiescence, and Cdk7 accelerates Cdk4 activation in vitro, establishing a CDK-activation cascade during G1 progression.","method":"Chemical genetics (analog-sensitive Cdk7), in vitro Cdk4 activation assay, cell quiescence/exit experiments, phosphorylation time course","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — chemical genetic dissection plus in vitro activation assay with quiescence rescue","pmids":["23622515"],"is_preprint":false},{"year":2013,"finding":"Cdk4 loss abrogates centrosome amplification and binucleation in HER2+ breast cancer cells; Nek2 protein levels decrease upon Cdk4 knockdown and vice versa, indicating a molecular connection whereby Cdk4 signals centrosome amplification through Nek2, and defective cytokinesis (normalized by Cdk4 downregulation) is the source of binucleation.","method":"shRNA knockdown, Nek2 overexpression, centrosome/cell cycle analysis in HER2+ cell lines","journal":"PloS one","confidence":"Medium","confidence_rationale":"Tier 3 — knockdown and reciprocal expression analysis, single lab","pmids":["23776583"],"is_preprint":false},{"year":2014,"finding":"Cyclin D1-CDK4 phosphorylates and activates GCN5 acetyltransferase, which then acetylates and inhibits PGC-1α activity on gluconeogenic genes, thereby suppressing hepatic glucose production independently of cell cycle progression; insulin/GSK-3β signaling stabilizes nuclear cyclin D1, and dietary amino acids increase hepatic cyclin D1 mRNA.","method":"Cell-based high-throughput chemical screen, in vitro kinase assay (CDK4 phosphorylating GCN5), PGC-1α acetylation assay, Cdk4−/− mouse metabolic phenotype, Cdk4 inhibitor treatment","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — in vitro kinase assay demonstrating direct GCN5 phosphorylation, multiple genetic and pharmacologic validations","pmids":["24870244"],"is_preprint":false},{"year":2014,"finding":"PD0332991 (palbociclib) inhibits CDK4/6 activity but paradoxically stabilizes activated cyclin D3-CDK4/6 complexes that are devoid of p21/p27; the inhibitor has opposite effects on p21-bound versus p21-free CDK4/6 complexes, and stabilized activated complexes persist for ≥24 h after drug removal, causing paradoxical cell cycle entry without mitogenic stimulation.","method":"CDK4/6 complex purification, phosphorylation state analysis, cell cycle assay after drug washout","journal":"Cell cycle","confidence":"Medium","confidence_rationale":"Tier 2 — biochemical dissection of p21-bound vs. p21-free complexes with functional cell cycle consequence","pmids":["25486476"],"is_preprint":false},{"year":2017,"finding":"CDK4 directly phosphorylates AMPKα2 to inhibit its activity, thereby repressing fatty acid oxidation and promoting anaerobic glycolysis; Cdk4−/− mice have increased oxidative metabolism and exercise capacity, and CDK4 inhibition mimics this metabolic shift in an AMPK-dependent manner in skeletal muscle.","method":"In vitro kinase assay (CDK4 phosphorylating AMPKα2), non-phosphorylatable AMPKα2 mutants, CDK4 inhibitor treatment, Cdk4−/− mouse exercise phenotype, AMPK-deficient muscle epistasis","journal":"Molecular cell","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro phosphorylation plus mutagenesis and in vivo genetic epistasis","pmids":["29053957"],"is_preprint":false},{"year":2017,"finding":"Cyclin D-CDK4 phosphorylates SPOP (speckle-type POZ protein), promoting SPOP degradation via FZR1/APC; this stabilizes PD-L1 protein. When CDK4/6 is inhibited, SPOP degradation is prevented, enabling SPOP to ubiquitinate PD-L1 via cullin 3 for proteasomal degradation, thus reducing PD-L1 levels and increasing tumor-infiltrating lymphocytes.","method":"In vitro CDK4 kinase assay on SPOP, co-immunoprecipitation, ubiquitination assay, CDK4/6 inhibitor treatment in vivo, SPOP loss-of-function mutations in tumors","journal":"Nature","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro kinase assay, ubiquitination reconstitution, in vivo mouse validation","pmids":["29160310"],"is_preprint":false},{"year":2017,"finding":"CDK4/6 inhibitors activate tumor cell expression of endogenous retroviral elements, increasing intracellular double-stranded RNA and stimulating type III interferon production; CDK4/6 inhibitors also markedly suppress regulatory T cell proliferation; both effects involve reduced activity of the E2F target DNMT1, promoting anti-tumor immunity.","method":"Mouse tumor models, transcriptomic analysis of clinical trial biopsies, regulatory T cell proliferation assay, dsRNA/IFN measurement","journal":"Nature","confidence":"High","confidence_rationale":"Tier 2 — multiple mechanistic arms tested in preclinical models and clinical specimens","pmids":["28813415"],"is_preprint":false},{"year":2017,"finding":"CyclinD/Cdk4 phosphorylates TSC1/2 in Drosophila wing disc cells at the G1/S transition, activating TORC1; this reveals a conserved mechanism linking cell cycle progression to nutrient sensing via Cdk4.","method":"In situ TORC1 activity readout (anti-phospho-dRpS6 antibody), genetic epistasis in Drosophila wing disc, CycD/Cdk4 overexpression","journal":"Developmental cell","confidence":"Medium","confidence_rationale":"Tier 2 — in vivo genetic epistasis in Drosophila with novel TORC1 activity reporter; ortholog findings consistent with mammalian CDK4","pmids":["28829945"],"is_preprint":false},{"year":2017,"finding":"CyclinD1-CDK4 directly phosphorylates CDC25A on Ser40 during G1, promoting CDC25A degradation in a βTrCP-dependent manner, thus generating a negative feedback loop controlling the G1/S transition.","method":"In vitro kinase assay (cyclin D1-CDK4 on CDC25A), phosphorylation mapping (Ser40), βTrCP-dependent stability assay, cell cycle synchrony","journal":"Oncogene","confidence":"High","confidence_rationale":"Tier 1 — direct in vitro kinase assay with site identification and degradation mechanism","pmids":["28192398"],"is_preprint":false},{"year":2018,"finding":"CDK4/6 phosphorylates EZH2 in keratinocytes, triggering EZH2-mediated methylation-induced STAT3 activation; active STAT3 induces IκBζ, a proinflammatory transcription factor required for cytokine synthesis in psoriasis; pharmacological or genetic inhibition of CDK4/6 or EZH2 suppresses IκBζ and psoriatic gene expression.","method":"In vitro CDK4/6 kinase assay on EZH2, STAT3 methylation/activation assay, CDK4/6i and EZH2i treatment in keratinocytes and mouse psoriasis models","journal":"The Journal of clinical investigation","confidence":"High","confidence_rationale":"Tier 1-2 — direct kinase assay, downstream signaling pathway dissection, in vivo mouse model validation","pmids":["32701505"],"is_preprint":false},{"year":2018,"finding":"Fkbp5 promotes myoblast differentiation through two CDK4-specific mechanisms: (1) it sequesters CDK4 within the Hsp90 storage complex, preventing cyclin D1-CDK4 complex formation; (2) it promotes cis-trans isomerization of the Thr172-Pro173 peptide bond in CDK4, inhibiting Thr172 phosphorylation (required for CDK4 activation). Fkbp5−/− mice show delayed muscle regeneration.","method":"Co-immunoprecipitation, peptidyl prolyl isomerization assay, Thr172 phosphorylation assay, Fkbp5−/− mouse muscle regeneration, comparison with Fkbp4","journal":"Cell reports","confidence":"High","confidence_rationale":"Tier 1-2 — novel isomerization mechanism demonstrated biochemically with genetic in vivo validation","pmids":["30485818"],"is_preprint":false},{"year":2019,"finding":"CDK4 phosphorylates folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids; CDK4 also directly regulates lysosomal function and is essential for lysosomal degradation, thereby regulating mTORC1 activity; CDK4 loss leads to lysosomal dysfunction, impaired autophagic flux, and cancer cell senescence.","method":"In vitro CDK4 kinase assay on FLCN, lysosomal function assays, mTORC1 recruitment imaging, CDK4 inhibitor and genetic inactivation in xenograft models","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 1-2 — direct substrate phosphorylation assay, lysosomal functional assay, in vivo xenograft validation","pmids":["31395606"],"is_preprint":false},{"year":2019,"finding":"CDK4 interaction with CDKN2A (p16INK4a family proteins) in cells prevents palbociclib from engaging CDK4; high CDKN2A causes drug insensitivity by occupying CDK4 before the inhibitor can bind, as shown by chemo-proteomics target engagement profiling in isogenic cells.","method":"Chemo-proteomics (activity-based protein profiling), isogenic cell lines with engineered CDKN2A levels, CDK4 target engagement assay","journal":"Molecular cancer therapeutics","confidence":"High","confidence_rationale":"Tier 2 — chemo-proteomics with isogenic controls, direct target engagement quantification","pmids":["30837298"],"is_preprint":false},{"year":2020,"finding":"CDK4/6 activity increases rapidly before CDK2 activity during cell cycle entry; stress signals in G1 can rapidly inactivate CDK4/6 to return cells to quiescence with decreasing probability as cells approach S phase, revealing CDK4/6 as the primary G1 activity determining quiescence exit timing and G1 length.","method":"Single-cell CDK4/6 and CDK2 activity reporter system (live imaging), stress signal perturbations","journal":"eLife","confidence":"High","confidence_rationale":"Tier 2 — live-cell single-cell reporters with direct functional consequence measurement","pmids":["32255427"],"is_preprint":false},{"year":2021,"finding":"CDK4-dependent activation of p38 MAPK determines cell size homeostasis; CDK4 activity sets the target size threshold at which p38 is inactivated to permit cell cycle progression, functioning analogously to a thermostat dial for cell size.","method":"CDK4 inhibition/activation experiments, p38 activity assays, cell size measurements, genetic perturbations","journal":"Developmental cell","confidence":"Medium","confidence_rationale":"Tier 2 — direct functional link between CDK4 activity and p38 activation in defined cell size context","pmids":["34022133"],"is_preprint":false},{"year":2021,"finding":"CDK6 upregulation confers resistance to CDK4/6 inhibitors by inducing and binding INK4 proteins (e.g., p18INK4C); the p18INK4C-cyclin D-CDK6 ternary complex occludes CDK4/6 inhibitor (palbociclib) binding while only weakly suppressing ATP binding, as shown by in vitro binding and kinase assays with physical modeling.","method":"In vitro binding assay, kinase assay, chemo-proteomics, physical modeling, PROTAC degrader development","journal":"Cancer discovery","confidence":"High","confidence_rationale":"Tier 1-2 — biochemical binding/kinase assays, structural modeling, PROTAC validation in vivo","pmids":["34544752"],"is_preprint":false},{"year":2023,"finding":"SETDB1 protects CDK4/6-phosphorylated RB (p-RB) from degradation; TRIM28 binds and promotes ubiquitination and proteasomal degradation of CDK4/6-phosphorylated RB; SETDB1 (via its Tudor domain binding to methylated RB, independent of methyltransferase activity) opposes TRIM28 to stabilize p-RB, identifying a CDK4/6-dependent, TRIM28-mediated RB inactivation mechanism.","method":"Co-immunoprecipitation, ubiquitination assay, SETDB1 Tudor domain mutant analysis, antisense oligonucleotide, palbociclib combination in vivo","journal":"Cancer research","confidence":"High","confidence_rationale":"Tier 2 — multiple biochemical assays, domain mutant analysis, in vivo validation","pmids":["36637424"],"is_preprint":false},{"year":2025,"finding":"Selective CDK4 inhibition (atirmociclib/PF-07220060) shows reduced neutropenia compared to dual CDK4/6 inhibitors because CDK4 is dispensable for hematopoiesis (where CDK6 dominates), while HR+ breast cancer cells are highly CDK4-dependent; greater CDK4 target coverage leads to deeper anti-tumor responses.","method":"Selective CDK4 inhibitor development, neutrophil toxicity assays, CDK4 vs. CDK6 selectivity profiling, HR+ breast cancer cell line sensitivity, in vivo tumor models","journal":"Cancer cell","confidence":"High","confidence_rationale":"Tier 1-2 — pharmacologic selectivity profiling with in vivo tumor and hematopoietic phenotypes","pmids":["40068598"],"is_preprint":false}],"current_model":"CDK4 is a serine/threonine kinase that, when bound to D-type cyclins and activated by CAK-mediated Thr172 phosphorylation (facilitated by Cdk7 and regulated by Fkbp5-mediated prolyl isomerization and Hsp90/Cdc37 chaperoning), phosphorylates RB to relieve E2F-mediated transcriptional repression and drive G1-to-S phase transition; CDK4 activity is negatively regulated by INK4 family proteins (p16, p15, p18, p19) competing with D-cyclins and positively modulated by CIP/KIP proteins (p21, p27) that scaffold active complexes; beyond cell cycle control, CDK4 directly phosphorylates GCN5, AMPKα2, FLCN, SPOP, EZH2, and CDC25A to regulate glucose metabolism, fatty acid oxidation, lysosomal/mTORC1 function, PD-L1 stability, and inflammatory signaling, while its transcription is induced by c-MYC; CDK4 R24C mutations found in familial melanoma abolish p16 binding without affecting p21/p27 binding, and CDK4 amplification or CDK6-INK4 complex formation mediates resistance to CDK4/6 inhibitors."},"narrative":{"teleology":[{"year":1993,"claim":"The identification of p16INK4a as a direct CDK4 inhibitor and the reconstitution of CDK4/cyclin D-dependent Rb phosphorylation established the core p16–CDK4/cyclin D–Rb–E2F pathway governing G1/S progression.","evidence":"In vitro kinase inhibition assays, baculovirus/Sf9 reconstitution of CDK4/cyclin D complexes, E2F release assays, co-IP in normal vs. SV40-transformed fibroblasts","pmids":["8259215","8449399","8101826"],"confidence":"High","gaps":["Mechanism of CDK4 enzymatic activation (activating kinase) unknown at this stage","Stoichiometry and competition between p16 and cyclins for CDK4 binding not yet defined"]},{"year":1994,"claim":"Discovery that CAK (Cdk7/cyclin H) phosphorylates CDK4 on Thr172 for activation, and that CIP/KIP proteins promote CDK4/cyclin D assembly and nuclear targeting, resolved how CDK4 is activated and how its complexes are assembled in a regulated manner.","evidence":"In vitro reconstitution with p39MO15/cyclin H, immune-depletion, quantitative assembly kinetics, subcellular fractionation","pmids":["7935441","9106657"],"confidence":"High","gaps":["Whether Cdk7 is the sole CDK4-activating kinase in vivo was not established","CIP/KIP titration model (assembly vs. inhibition) not fully resolved"]},{"year":1994,"claim":"The expansion of the INK4 family (p15INK4B, p18INK4C, p19INK4D) revealed that CDK4/6 activity is controlled by a family of structurally related competitive inhibitors, some induced by extracellular signals like TGF-β.","evidence":"cDNA isolation, yeast two-hybrid, kinase inhibition assays, TGF-β induction in keratinocytes, retroviral overexpression and cell cycle analysis","pmids":["8078588","8001816","7739547","8741839"],"confidence":"High","gaps":["Relative contribution of individual INK4 members in specific tissues not yet determined","Structural basis for INK4–CDK4 competition with cyclins not resolved"]},{"year":1995,"claim":"The CDK4 R24C mutation in melanoma and its confirmation as a familial melanoma susceptibility allele demonstrated that p16-CDK4 binding is a critical tumor-suppressor axis in human cancer.","evidence":"Mutation sequencing from melanoma tissue and familial kindreds, p16/p21/p27 binding assays, CTL recognition assay","pmids":["7652577","8528263"],"confidence":"High","gaps":["Whether R24C alters CDK4 kinase activity per se or only p16 binding was not fully dissected","Tissue specificity of melanoma susceptibility not mechanistically explained"]},{"year":1999,"claim":"Mechanistic dissection of ordered Rb inactivation showed that CDK4/6 first phosphorylates the Rb C-terminus to displace HDAC, while CDK2 subsequently disrupts the pocket domain to release E2F, establishing a two-step Rb inactivation model.","evidence":"In vitro phosphorylation with defined Rb mutants, HDAC binding assays, co-immunoprecipitation","pmids":["10499802"],"confidence":"High","gaps":["Whether this ordered phosphorylation sequence operates identically in all cell types was untested","Full complement of CDK4-specific Rb phosphorylation sites not mapped"]},{"year":2000,"claim":"The discovery that c-MYC transcriptionally activates CDK4 placed CDK4 downstream of a major oncogenic transcription factor, integrating mitogenic signaling with cell cycle kinase expression.","evidence":"SAGE, promoter binding assay, ectopic CDK4 rescue of c-MYC-deficient RAT1 cells","pmids":["10688915"],"confidence":"High","gaps":["Whether MYC-dependent CDK4 induction is rate-limiting for proliferation in most contexts was unclear"]},{"year":2001,"claim":"CDK4 R24C knock-in mice confirmed that INK4-insensitive CDK4 is sufficient to initiate melanoma in vivo, and genetic epistasis established a hierarchy among INK4 family members (p18 > p15) in melanocyte tumor suppression.","evidence":"Knock-in mouse model, carcinogen treatment, tumor sequencing, genetic crosses with INK4 knockouts","pmids":["11606789"],"confidence":"High","gaps":["Molecular mechanism of melanocyte-specific CDK4 dependency not resolved","Contribution of CDK6 in this tissue not assessed"]},{"year":2006,"claim":"Structural and genetic studies revealed that Hsp90/Cdc37 chaperone CDK4 as a ternary complex, and that combined CDK4/CDK2 loss causes embryonic lethality due to Rb hypo-phosphorylation, confirming CDK4 cooperates with CDK2 to inactivate Rb in vivo.","evidence":"Single-particle EM of Hsp90-Cdc37-Cdk4, double knockout mice, HPV-E7 rescue experiments","pmids":["16949366","16678773"],"confidence":"High","gaps":["How Cdc37 specifically recognizes CDK4 over other kinases remained unclear","Tissue-specific requirements for CDK4 vs. CDK2 not fully delineated"]},{"year":2013,"claim":"Chemical genetic proof that Cdk7 is the physiological CDK4-activating kinase, required to maintain (not just establish) CDK4 activity during G1 exit, defined the upstream CDK activation cascade.","evidence":"Analog-sensitive Cdk7 allele, in vitro Cdk4 activation, cell quiescence/exit phosphorylation time course","pmids":["23622515"],"confidence":"High","gaps":["Whether Cdk7 regulation of CDK4 vs. CDK6 differs quantitatively was not resolved"]},{"year":2014,"claim":"CDK4 was shown to directly phosphorylate GCN5, suppressing hepatic gluconeogenesis independently of cell cycle control, establishing CDK4 as a metabolic kinase linking insulin/amino acid signaling to glucose homeostasis.","evidence":"In vitro CDK4 kinase assay on GCN5, PGC-1α acetylation, Cdk4−/− mouse metabolic phenotype, CDK4 inhibitor treatment","pmids":["24870244"],"confidence":"High","gaps":["Full spectrum of CDK4 metabolic substrates not catalogued","Relative contributions of CDK4 vs. CDK6 to hepatic metabolism unclear"]},{"year":2017,"claim":"A burst of discoveries identified multiple non-Rb CDK4 substrates (AMPKα2, SPOP, CDC25A) and revealed CDK4/6 inhibitors stimulate anti-tumor immunity by activating endogenous retroviruses, linking CDK4 kinase activity to fatty acid oxidation, PD-L1 stability, G1/S feedback, and immune surveillance.","evidence":"In vitro kinase assays on AMPKα2/SPOP/CDC25A, Cdk4−/− mouse exercise phenotype, AMPK epistasis, ubiquitination reconstitution, tumor-infiltrating lymphocyte analysis, dsRNA/IFN measurement in preclinical models and clinical biopsies","pmids":["29053957","29160310","28192398","28813415"],"confidence":"High","gaps":["Structural basis for CDK4 recognition of diverse non-Rb substrates unknown","Whether SPOP phosphorylation occurs at physiological CDK4 activity levels in all tumor types not established"]},{"year":2018,"claim":"Fkbp5 was identified as a CDK4-specific regulator that both sequesters CDK4 within Hsp90 complexes and inhibits Thr172 phosphorylation through prolyl isomerization, providing a novel conformational gating mechanism for CDK4 activation during myogenic differentiation.","evidence":"Prolyl isomerase assay, Thr172 phosphorylation analysis, Fkbp5−/− mouse muscle regeneration","pmids":["30485818"],"confidence":"High","gaps":["Whether other prolyl isomerases similarly regulate CDK4 is unknown","Generalizability beyond muscle differentiation not tested"]},{"year":2019,"claim":"CDK4 was shown to phosphorylate FLCN to regulate lysosomal mTORC1 recruitment in response to amino acids, extending CDK4's metabolic functions to nutrient-sensing and lysosomal biology, while chemo-proteomics revealed that high p16/CDKN2A levels prevent palbociclib engagement of CDK4.","evidence":"In vitro CDK4 kinase assay on FLCN, lysosomal function assays, mTORC1 imaging, chemo-proteomics target engagement in isogenic CDKN2A cell lines","pmids":["31395606","30837298"],"confidence":"High","gaps":["Whether CDK4-FLCN axis operates independently of Rb phosphorylation in all contexts unclear","No crystal structure of CDK4-FLCN complex"]},{"year":2020,"claim":"Live single-cell imaging established that CDK4/6 activity rises before CDK2 activity during cell cycle entry and that stress signals can rapidly inactivate CDK4/6 to return cells to quiescence, positioning CDK4/6 as the primary G1 activity sensor determining quiescence exit.","evidence":"Single-cell CDK4/6 and CDK2 live-cell activity reporters, stress perturbation experiments","pmids":["32255427"],"confidence":"High","gaps":["Molecular identity of stress signals that inactivate CDK4/6 not fully defined","Whether CDK4 and CDK6 contribute equally in this reporter system is unresolved"]},{"year":2021,"claim":"CDK6 upregulation was shown to confer CDK4/6 inhibitor resistance through formation of p18INK4C-cyclin D-CDK6 ternary complexes that occlude drug binding while retaining kinase activity, explaining a major clinical resistance mechanism and motivating selective CDK4 inhibitor development.","evidence":"In vitro binding/kinase assays, chemo-proteomics, physical modeling, PROTAC degrader validation in vivo","pmids":["34544752"],"confidence":"High","gaps":["Whether resistance-conferring ternary complexes form in all tumor contexts untested","Structural details of drug occlusion at atomic resolution lacking"]},{"year":2025,"claim":"Selective CDK4 inhibition demonstrated that CDK4 is dispensable for hematopoiesis (CDK6-dependent) while essential for HR+ breast cancer cell proliferation, establishing a therapeutic window for selective CDK4 targeting with reduced neutropenia.","evidence":"Selective CDK4 inhibitor profiling, neutrophil toxicity assays, CDK4 vs. CDK6 selectivity, HR+ breast cancer models","pmids":["40068598"],"confidence":"High","gaps":["Long-term resistance mechanisms to selective CDK4 inhibitors not characterized","Whether selective CDK4 inhibition preserves the immune-stimulatory effects of dual CDK4/6 inhibition is unknown"]},{"year":null,"claim":"Outstanding questions include the structural basis for CDK4 substrate recognition across its diverse non-Rb targets, the extent to which CDK4 metabolic and immune functions are Rb-independent, and how CDK4 and CDK6 are differentially deployed across tissues and tumor types.","evidence":"","pmids":[],"confidence":"High","gaps":["No high-resolution structure of CDK4 bound to non-Rb substrates","Rb-independent vs. Rb-dependent contributions of CDK4 not systematically dissected","Tissue-specific CDK4 vs. CDK6 functional partitioning incompletely mapped"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0140096","term_label":"catalytic activity, acting on a protein","supporting_discovery_ids":[1,3,17,27,29,30,33,34,36]},{"term_id":"GO:0016740","term_label":"transferase activity","supporting_discovery_ids":[1,3,27,29,30,33,34,36]}],"localization":[{"term_id":"GO:0005634","term_label":"nucleus","supporting_discovery_ids":[4,22]},{"term_id":"GO:0005829","term_label":"cytosol","supporting_discovery_ids":[4,20]}],"pathway":[{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[0,1,3,4,17,21,25,33,38]},{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[23,29,34,36,39]},{"term_id":"R-HSA-1430728","term_label":"Metabolism","supporting_discovery_ids":[27,29]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[9,14,19,40,42]},{"term_id":"R-HSA-168256","term_label":"Immune System","supporting_discovery_ids":[30,31]}],"complexes":["Cyclin D1-CDK4","Cyclin D2-CDK4","Cyclin D3-CDK4","Hsp90-Cdc37-CDK4"],"partners":["CCND1","CCND2","CCND3","CDKN2A","CDKN1A","CDKN1B","CDC37","FKBP5"],"other_free_text":[]},"mechanistic_narrative":"CDK4 is a D-type cyclin-dependent serine/threonine kinase that functions as a master regulator of the G1-to-S phase cell cycle transition and integrates mitogenic, metabolic, and immune-regulatory signals. Upon binding D-type cyclins (assembled with the aid of CIP/KIP scaffold proteins p21/p27), CDK4 is activated by CAK/Cdk7-mediated phosphorylation of Thr172 and sequentially phosphorylates Rb to displace HDAC, relieve E2F-mediated transcriptional repression, and commit cells to S-phase entry; this activation is negatively regulated by INK4 family inhibitors (p16, p15, p18, p19) that compete with D-cyclins for CDK4 binding, modulated by Hsp90/Cdc37 chaperoning and Fkbp5-mediated prolyl isomerization of the T-loop [PMID:8449399, PMID:7935441, PMID:10499802, PMID:23622515, PMID:30485818]. Beyond Rb, CDK4 directly phosphorylates GCN5 to suppress hepatic gluconeogenesis, AMPKα2 to inhibit fatty acid oxidation, FLCN to regulate lysosomal mTORC1 recruitment, SPOP to stabilize PD-L1, EZH2 to activate STAT3-driven inflammatory gene expression, and CDC25A to generate a G1/S negative-feedback loop [PMID:24870244, PMID:29053957, PMID:31395606, PMID:29160310, PMID:32701505, PMID:28192398]. Germline CDK4 R24C mutations that abolish p16 binding cause familial melanoma susceptibility [PMID:8528263, PMID:7652577]."},"prefetch_data":{"uniprot":{"accession":"P11802","full_name":"Cyclin-dependent kinase 4","aliases":["Cell division protein kinase 4","PSK-J3"],"length_aa":303,"mass_kda":33.7,"function":"Ser/Thr-kinase component of cyclin D-CDK4 (DC) complexes that phosphorylate and inhibit members of the retinoblastoma (RB) protein family including RB1 and regulate the cell-cycle during G(1)/S transition. Phosphorylation of RB1 allows dissociation of the transcription factor E2F from the RB/E2F complexes and the subsequent transcription of E2F target genes which are responsible for the progression through the G(1) phase. Hypophosphorylates RB1 in early G(1) phase. Cyclin D-CDK4 complexes are major integrators of various mitogenenic and antimitogenic signals. Also phosphorylates SMAD3 in a cell-cycle-dependent manner and represses its transcriptional activity. Component of the ternary complex, cyclin D/CDK4/CDKN1B, required for nuclear translocation and activity of the cyclin D-CDK4 complex","subcellular_location":"Cytoplasm; Nucleus; Nucleus membrane","url":"https://www.uniprot.org/uniprotkb/P11802/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":true,"resolved_as":"","url":"https://depmap.org/portal/gene/CDK4","classification":"Common Essential","n_dependent_lines":778,"n_total_lines":1208,"dependency_fraction":0.6440397350993378},"opencell":{"profiled":true,"resolved_as":"","ensg_id":"ENSG00000135446","cell_line_id":"CID001149","localizations":[{"compartment":"cytoplasmic","grade":3},{"compartment":"nucleoplasm","grade":3}],"interactors":[{"gene":"CDKN2C","stoichiometry":10.0},{"gene":"ANKRD52","stoichiometry":0.2},{"gene":"DSG1","stoichiometry":0.2},{"gene":"CDKN2A","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/target/CID001149","total_profiled":1310},"omim":[{"mim_id":"621507","title":"MICROCEPHALY 31, PRIMARY, AUTOSOMAL RECESSIVE; MCPH31","url":"https://www.omim.org/entry/621507"},{"mim_id":"620524","title":"DDB1- AND CUL4-ASSOCIATED FACTOR 16; DCAF16","url":"https://www.omim.org/entry/620524"},{"mim_id":"617891","title":"ZINC FINGER PROTEIN 655; ZNF655","url":"https://www.omim.org/entry/617891"},{"mim_id":"615134","title":"MELANOMA, CUTANEOUS MALIGNANT, SUSCEPTIBILITY TO, 9; CMM9","url":"https://www.omim.org/entry/615134"},{"mim_id":"614084","title":"WEE1 HOMOLOG 2; WEE2","url":"https://www.omim.org/entry/614084"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"Supported","locations":[{"location":"Nucleoplasm","reliability":"Supported"},{"location":"Cytosol","reliability":"Supported"},{"location":"Nuclear membrane","reliability":"Additional"},{"location":"Nucleoli","reliability":"Additional"}],"tissue_specificity":"Low tissue specificity","tissue_distribution":"Detected in all","driving_tissues":[],"url":"https://www.proteinatlas.org/search/CDK4"},"hgnc":{"alias_symbol":["PSK-J3"],"prev_symbol":[]},"alphafold":{"accession":"P11802","domains":[{"cath_id":"3.30.200.20","chopping":"7-93","consensus_level":"high","plddt":82.7385,"start":7,"end":93},{"cath_id":"1.10.510.10","chopping":"98-156_177-294","consensus_level":"high","plddt":95.5041,"start":98,"end":294}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/P11802","model_url":"https://alphafold.ebi.ac.uk/files/AF-P11802-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-P11802-F1-predicted_aligned_error_v6.png","plddt_mean":86.81},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=CDK4","jax_strain_url":"https://www.jax.org/strain/search?query=CDK4"},"sequence":{"accession":"P11802","fasta_url":"https://rest.uniprot.org/uniprotkb/P11802.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/P11802/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/P11802"}},"corpus_meta":[{"pmid":"28813415","id":"PMC_28813415","title":"CDK4/6 inhibition triggers anti-tumour immunity.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28813415","citation_count":1165,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27030077","id":"PMC_27030077","title":"Treating cancer with selective CDK4/6 inhibitors.","date":"2016","source":"Nature reviews. Clinical oncology","url":"https://pubmed.ncbi.nlm.nih.gov/27030077","citation_count":891,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26658964","id":"PMC_26658964","title":"Targeting CDK4 and CDK6: From Discovery to Therapy.","date":"2015","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/26658964","citation_count":735,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10688915","id":"PMC_10688915","title":"Identification of CDK4 as a target of c-MYC.","date":"2000","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/10688915","citation_count":408,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35304604","id":"PMC_35304604","title":"Targeting CDK4 and CDK6 in cancer.","date":"2022","source":"Nature reviews. Cancer","url":"https://pubmed.ncbi.nlm.nih.gov/35304604","citation_count":386,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30061045","id":"PMC_30061045","title":"CDK4/6 Inhibition in Cancer: Beyond Cell Cycle Arrest.","date":"2018","source":"Trends in cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/30061045","citation_count":366,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8221695","id":"PMC_8221695","title":"Coamplification of the CDK4 gene with MDM2 and GLI in human sarcomas.","date":"1993","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/8221695","citation_count":362,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35025636","id":"PMC_35025636","title":"CDK4 and CDK6 kinases: From basic science to cancer therapy.","date":"2022","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/35025636","citation_count":351,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32289274","id":"PMC_32289274","title":"Mechanisms of Sensitivity and Resistance to CDK4/6 Inhibition.","date":"2020","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/32289274","citation_count":307,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16949366","id":"PMC_16949366","title":"Structure of an Hsp90-Cdc37-Cdk4 complex.","date":"2006","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16949366","citation_count":247,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24795392","id":"PMC_24795392","title":"Molecular pathways: CDK4 inhibitors for cancer therapy.","date":"2014","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/24795392","citation_count":201,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"24870244","id":"PMC_24870244","title":"Cyclin D1-Cdk4 controls glucose metabolism independently of cell cycle progression.","date":"2014","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24870244","citation_count":193,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7935441","id":"PMC_7935441","title":"Activation of cyclin-dependent kinase 4 (cdk4) by mouse MO15-associated kinase.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7935441","citation_count":190,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32723562","id":"PMC_32723562","title":"Cyclin D-CDK4/6 functions in cancer.","date":"2020","source":"Advances in cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/32723562","citation_count":168,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23622515","id":"PMC_23622515","title":"A Cdk7-Cdk4 T-loop phosphorylation cascade promotes G1 progression.","date":"2013","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/23622515","citation_count":147,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32899866","id":"PMC_32899866","title":"Targeting Cell Cycle in Breast Cancer: CDK4/6 Inhibitors.","date":"2020","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/32899866","citation_count":141,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30959874","id":"PMC_30959874","title":"Updates on the CDK4/6 Inhibitory Strategy and Combinations in Breast Cancer.","date":"2019","source":"Cells","url":"https://pubmed.ncbi.nlm.nih.gov/30959874","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11606789","id":"PMC_11606789","title":"Invasive melanoma in Cdk4-targeted mice.","date":"2001","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/11606789","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16678773","id":"PMC_16678773","title":"Combined loss of Cdk2 and Cdk4 results in embryonic lethality and Rb hypophosphorylation.","date":"2006","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/16678773","citation_count":126,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34544752","id":"PMC_34544752","title":"INK4 Tumor Suppressor Proteins Mediate Resistance to CDK4/6 Kinase Inhibitors.","date":"2021","source":"Cancer discovery","url":"https://pubmed.ncbi.nlm.nih.gov/34544752","citation_count":124,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32357912","id":"PMC_32357912","title":"The application and prospect of CDK4/6 inhibitors in malignant solid tumors.","date":"2020","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/32357912","citation_count":121,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32541838","id":"PMC_32541838","title":"Senescence as a therapeutically relevant response to CDK4/6 inhibitors.","date":"2020","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/32541838","citation_count":120,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34327137","id":"PMC_34327137","title":"Clinical and Pharmacologic Differences of CDK4/6 Inhibitors in Breast Cancer.","date":"2021","source":"Frontiers in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/34327137","citation_count":118,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19597485","id":"PMC_19597485","title":"The CDK4-pRB-E2F1 pathway controls insulin secretion.","date":"2009","source":"Nature cell biology","url":"https://pubmed.ncbi.nlm.nih.gov/19597485","citation_count":111,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8898364","id":"PMC_8898364","title":"Induction of p18INK4c and its predominant association with CDK4 and CDK6 during myogenic differentiation.","date":"1996","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/8898364","citation_count":109,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8741839","id":"PMC_8741839","title":"Isolation and characterization of p19INK4d, a p16-related inhibitor specific to CDK6 and CDK4.","date":"1996","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/8741839","citation_count":106,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25876993","id":"PMC_25876993","title":"The Role of CDK4/6 Inhibition in Breast Cancer.","date":"2015","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/25876993","citation_count":104,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25028469","id":"PMC_25028469","title":"Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo.","date":"2014","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/25028469","citation_count":103,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10580009","id":"PMC_10580009","title":"Regulation of CDK4 activity by a novel CDK4-binding protein, p34(SEI-1).","date":"1999","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/10580009","citation_count":100,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"19383288","id":"PMC_19383288","title":"Mice thrive without Cdk4 and Cdk2.","date":"2007","source":"Molecular oncology","url":"https://pubmed.ncbi.nlm.nih.gov/19383288","citation_count":97,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29739788","id":"PMC_29739788","title":"MAPK Reliance via Acquired CDK4/6 Inhibitor Resistance in Cancer.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/29739788","citation_count":92,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28629371","id":"PMC_28629371","title":"Combined targeting of MDM2 and CDK4 is synergistic in dedifferentiated liposarcomas.","date":"2017","source":"Journal of hematology & oncology","url":"https://pubmed.ncbi.nlm.nih.gov/28629371","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28814434","id":"PMC_28814434","title":"Combined CDK4/6 and mTOR Inhibition Is Synergistic against Glioblastoma via Multiple Mechanisms.","date":"2017","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/28814434","citation_count":89,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"7738717","id":"PMC_7738717","title":"MDM2 and CDK4 gene amplification in Ewing's sarcoma.","date":"1995","source":"The Journal of pathology","url":"https://pubmed.ncbi.nlm.nih.gov/7738717","citation_count":87,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35982377","id":"PMC_35982377","title":"Overexpressed Cyclin D1 and CDK4 proteins are responsible for the resistance to CDK4/6 inhibitor in breast cancer that can be reversed by PI3K/mTOR inhibitors.","date":"2022","source":"Science China. Life sciences","url":"https://pubmed.ncbi.nlm.nih.gov/35982377","citation_count":85,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32068118","id":"PMC_32068118","title":"A unique CDK4/6 inhibitor: Current and future therapeutic strategies of abemaciclib.","date":"2020","source":"Pharmacological research","url":"https://pubmed.ncbi.nlm.nih.gov/32068118","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21477379","id":"PMC_21477379","title":"Elevated expression of CDK4 in lung cancer.","date":"2011","source":"Journal of translational medicine","url":"https://pubmed.ncbi.nlm.nih.gov/21477379","citation_count":84,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27986745","id":"PMC_27986745","title":"Dual ALK and CDK4/6 Inhibition Demonstrates Synergy against Neuroblastoma.","date":"2016","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/27986745","citation_count":78,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25810375","id":"PMC_25810375","title":"CDK4 Amplification Reduces Sensitivity to CDK4/6 Inhibition in Fusion-Positive Rhabdomyosarcoma.","date":"2015","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/25810375","citation_count":77,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30397176","id":"PMC_30397176","title":"A Combination CDK4/6 and IGF1R Inhibitor Strategy for Ewing Sarcoma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30397176","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30084835","id":"PMC_30084835","title":"Combined CDK4/6 and Pan-mTOR Inhibition Is Synergistic Against Intrahepatic Cholangiocarcinoma.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30084835","citation_count":75,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32255427","id":"PMC_32255427","title":"Stress-mediated exit to quiescence restricted by increasing persistence in CDK4/6 activation.","date":"2020","source":"eLife","url":"https://pubmed.ncbi.nlm.nih.gov/32255427","citation_count":73,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"21084836","id":"PMC_21084836","title":"STAT1 interacts directly with cyclin D1/Cdk4 and mediates cell cycle arrest.","date":"2010","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/21084836","citation_count":72,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"9291427","id":"PMC_9291427","title":"Altered expression of cyclin D1 and CDK4 genes in ovarian carcinomas.","date":"1997","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/9291427","citation_count":65,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"17092340","id":"PMC_17092340","title":"Regulation of CDK4.","date":"2006","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/17092340","citation_count":62,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30125344","id":"PMC_30125344","title":"JMJD6 promotes hepatocellular carcinoma carcinogenesis by targeting CDK4.","date":"2018","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/30125344","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29053957","id":"PMC_29053957","title":"CDK4 Phosphorylates AMPKα2 to Inhibit Its Activity and Repress Fatty Acid Oxidation.","date":"2017","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/29053957","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33364954","id":"PMC_33364954","title":"Mechanisms of CDK4/6 Inhibitor Resistance in Luminal Breast Cancer.","date":"2020","source":"Frontiers in pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/33364954","citation_count":59,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8175758","id":"PMC_8175758","title":"Purification of a 15-kDa cdk4- and cdk5-binding protein.","date":"1994","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/8175758","citation_count":58,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29935900","id":"PMC_29935900","title":"Mechanisms of therapeutic CDK4/6 inhibition in breast cancer.","date":"2017","source":"Seminars in oncology","url":"https://pubmed.ncbi.nlm.nih.gov/29935900","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26418250","id":"PMC_26418250","title":"Impact of cyclin-dependent kinase CDK4 inhibition on eryptosis.","date":"2015","source":"Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology","url":"https://pubmed.ncbi.nlm.nih.gov/26418250","citation_count":57,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11311493","id":"PMC_11311493","title":"Alteration of cyclin D1 and CDK4 gene in carcinoma of uterine cervix.","date":"2001","source":"Cancer letters","url":"https://pubmed.ncbi.nlm.nih.gov/11311493","citation_count":55,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26528855","id":"PMC_26528855","title":"Efficacy of CDK4 inhibition against sarcomas depends on their levels of CDK4 and p16ink4 mRNA.","date":"2015","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/26528855","citation_count":54,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10884881","id":"PMC_10884881","title":"Expression of p19INK4d, CDK4, CDK6 in glioblastoma multiforme.","date":"2000","source":"British journal of neurosurgery","url":"https://pubmed.ncbi.nlm.nih.gov/10884881","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28829945","id":"PMC_28829945","title":"CycD/Cdk4 and Discontinuities in Dpp Signaling Activate TORC1 in the Drosophila Wing Disc.","date":"2017","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/28829945","citation_count":52,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30224338","id":"PMC_30224338","title":"To Cycle or Fight-CDK4/6 Inhibitors at the Crossroads of Anticancer Immunity.","date":"2018","source":"Clinical cancer research : an official journal of the American Association for Cancer Research","url":"https://pubmed.ncbi.nlm.nih.gov/30224338","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31307887","id":"PMC_31307887","title":"Design of a brain-penetrant CDK4/6 inhibitor for glioblastoma.","date":"2019","source":"Bioorganic & medicinal chemistry letters","url":"https://pubmed.ncbi.nlm.nih.gov/31307887","citation_count":51,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"10390011","id":"PMC_10390011","title":"Mutation testing in melanoma families: INK4A, CDK4 and INK4D.","date":"1999","source":"British journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/10390011","citation_count":49,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32546660","id":"PMC_32546660","title":"Chemotherapy and CDK4/6 Inhibitors: Unexpected Bedfellows.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32546660","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35479560","id":"PMC_35479560","title":"CDK4/6 inhibitors: a brief overview and prospective research directions.","date":"2021","source":"RSC advances","url":"https://pubmed.ncbi.nlm.nih.gov/35479560","citation_count":47,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32701505","id":"PMC_32701505","title":"The CDK4/6-EZH2 pathway is a potential therapeutic target for psoriasis.","date":"2020","source":"The Journal of clinical investigation","url":"https://pubmed.ncbi.nlm.nih.gov/32701505","citation_count":44,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"26318986","id":"PMC_26318986","title":"CDK4/6 Inhibition Controls Proliferation of Bladder Cancer and Transcription of RB1.","date":"2015","source":"The Journal of urology","url":"https://pubmed.ncbi.nlm.nih.gov/26318986","citation_count":43,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32523378","id":"PMC_32523378","title":"Current Therapeutic Progress of CDK4/6 Inhibitors in Breast Cancer.","date":"2020","source":"Cancer management and research","url":"https://pubmed.ncbi.nlm.nih.gov/32523378","citation_count":41,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30858922","id":"PMC_30858922","title":"The interplay of CDK4 and CDK6 in melanoma.","date":"2019","source":"Oncotarget","url":"https://pubmed.ncbi.nlm.nih.gov/30858922","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25486476","id":"PMC_25486476","title":"The CDK4/CDK6 inhibitor PD0332991 paradoxically stabilizes activated cyclin D3-CDK4/6 complexes.","date":"2014","source":"Cell cycle (Georgetown, Tex.)","url":"https://pubmed.ncbi.nlm.nih.gov/25486476","citation_count":40,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31555743","id":"PMC_31555743","title":"SLC36A1-mTORC1 signaling drives acquired resistance to CDK4/6 inhibitors.","date":"2019","source":"Science advances","url":"https://pubmed.ncbi.nlm.nih.gov/31555743","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"23776583","id":"PMC_23776583","title":"Cdk4 and nek2 signal binucleation and centrosome amplification in a her2+ breast cancer model.","date":"2013","source":"PloS one","url":"https://pubmed.ncbi.nlm.nih.gov/23776583","citation_count":38,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"40068598","id":"PMC_40068598","title":"CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety.","date":"2025","source":"Cancer cell","url":"https://pubmed.ncbi.nlm.nih.gov/40068598","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28192398","id":"PMC_28192398","title":"CyclinD-CDK4/6 complexes phosphorylate CDC25A and regulate its stability.","date":"2017","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/28192398","citation_count":37,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31395606","id":"PMC_31395606","title":"CDK4 Regulates Lysosomal Function and mTORC1 Activation to Promote Cancer Cell Survival.","date":"2019","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/31395606","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34022133","id":"PMC_34022133","title":"Cell size homeostasis is maintained by CDK4-dependent activation of p38 MAPK.","date":"2021","source":"Developmental cell","url":"https://pubmed.ncbi.nlm.nih.gov/34022133","citation_count":36,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16759374","id":"PMC_16759374","title":"Cdk2 and Cdk4 cooperatively control the expression of Cdc2.","date":"2006","source":"Cell division","url":"https://pubmed.ncbi.nlm.nih.gov/16759374","citation_count":35,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"11063650","id":"PMC_11063650","title":"Inverse expression of Cdk4 and p16 in epithelial ovarian tumors.","date":"2000","source":"Gynecologic oncology","url":"https://pubmed.ncbi.nlm.nih.gov/11063650","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30837298","id":"PMC_30837298","title":"Direct CDKN2 Modulation of CDK4 Alters Target Engagement of CDK4 Inhibitor Drugs.","date":"2019","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/30837298","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"27391794","id":"PMC_27391794","title":"Roles of Cell Cyle Regulators Cyclin D1, CDK4, and p53 in Knee Osteoarthritis.","date":"2016","source":"Genetic testing and molecular biomarkers","url":"https://pubmed.ncbi.nlm.nih.gov/27391794","citation_count":34,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38277141","id":"PMC_38277141","title":"Cotargeting CDK4/6 and BRD4 Promotes Senescence and Ferroptosis Sensitivity in Cancer.","date":"2024","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/38277141","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37875500","id":"PMC_37875500","title":"Phase II trial of CDK4/6 inhibitor palbociclib in advanced sarcoma based on mRNA expression of CDK4/ CDKN2A.","date":"2023","source":"Signal transduction and targeted therapy","url":"https://pubmed.ncbi.nlm.nih.gov/37875500","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30485818","id":"PMC_30485818","title":"Promotion of Myoblast Differentiation by Fkbp5 via Cdk4 Isomerization.","date":"2018","source":"Cell reports","url":"https://pubmed.ncbi.nlm.nih.gov/30485818","citation_count":33,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32855282","id":"PMC_32855282","title":"Inducible deletion of CDK4 and CDK6 - deciphering CDK4/6 inhibitor effects in the hematopoietic system.","date":"2021","source":"Haematologica","url":"https://pubmed.ncbi.nlm.nih.gov/32855282","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35444175","id":"PMC_35444175","title":"Harnessing the immunotherapeutic potential of CDK4/6 inhibitors in melanoma: is timing everything?","date":"2022","source":"NPJ precision oncology","url":"https://pubmed.ncbi.nlm.nih.gov/35444175","citation_count":32,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"29392622","id":"PMC_29392622","title":"Clinical development of CDK4/6 inhibitor for breast cancer.","date":"2018","source":"Breast cancer (Tokyo, Japan)","url":"https://pubmed.ncbi.nlm.nih.gov/29392622","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"39930131","id":"PMC_39930131","title":"Targeting CDK4/6 in breast cancer.","date":"2025","source":"Experimental & molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39930131","citation_count":31,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28526299","id":"PMC_28526299","title":"MiR-200a Regulates CDK4/6 Inhibitor Effect by Targeting CDK6 in Metastatic Melanoma.","date":"2017","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/28526299","citation_count":30,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33803309","id":"PMC_33803309","title":"Development of CDK4/6 Inhibitors: A Five Years Update.","date":"2021","source":"Molecules (Basel, Switzerland)","url":"https://pubmed.ncbi.nlm.nih.gov/33803309","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8573142","id":"PMC_8573142","title":"Analysis of p16INK4a and its interaction with CDK4.","date":"1996","source":"Biochemical and biophysical research communications","url":"https://pubmed.ncbi.nlm.nih.gov/8573142","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"16108056","id":"PMC_16108056","title":"Proliferation and Cdk4 expression in microsatellite unstable colon cancers with TGFBR2 mutations.","date":"2006","source":"International journal of cancer","url":"https://pubmed.ncbi.nlm.nih.gov/16108056","citation_count":29,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"38424044","id":"PMC_38424044","title":"MYC induces CDK4/6 inhibitors resistance by promoting pRB1 degradation.","date":"2024","source":"Nature communications","url":"https://pubmed.ncbi.nlm.nih.gov/38424044","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"35917168","id":"PMC_35917168","title":"Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib.","date":"2022","source":"The oncologist","url":"https://pubmed.ncbi.nlm.nih.gov/35917168","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"25680902","id":"PMC_25680902","title":"MDM2 and CDK4 expression in periosteal osteosarcoma.","date":"2014","source":"Human pathology","url":"https://pubmed.ncbi.nlm.nih.gov/25680902","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"31954330","id":"PMC_31954330","title":"MicroRNA-129 Inhibits Glioma Cell Growth by Targeting CDK4, CDK6, and MDM2.","date":"2019","source":"Molecular therapy. Nucleic acids","url":"https://pubmed.ncbi.nlm.nih.gov/31954330","citation_count":28,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37182667","id":"PMC_37182667","title":"Immunomodulatory effects of CDK4/6 inhibitors.","date":"2023","source":"Biochimica et biophysica acta. Reviews on cancer","url":"https://pubmed.ncbi.nlm.nih.gov/37182667","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"28209757","id":"PMC_28209757","title":"CDK4/6 Therapeutic Intervention and Viable Alternative to Taxanes in CRPC.","date":"2017","source":"Molecular cancer research : MCR","url":"https://pubmed.ncbi.nlm.nih.gov/28209757","citation_count":26,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"30359883","id":"PMC_30359883","title":"Targeting CDK4/6 pathways and beyond in breast cancer.","date":"2018","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/30359883","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32712436","id":"PMC_32712436","title":"Getting under the skin: The role of CDK4/6 in melanomas.","date":"2020","source":"European journal of medicinal chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/32712436","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"37276679","id":"PMC_37276679","title":"Development of PROTAC degrader probe of CDK4/6 based on DCAF16.","date":"2023","source":"Bioorganic chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/37276679","citation_count":25,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"36637424","id":"PMC_36637424","title":"SETDB1 Modulates Degradation of Phosphorylated RB and Anticancer Efficacy of CDK4/6 Inhibitors.","date":"2023","source":"Cancer research","url":"https://pubmed.ncbi.nlm.nih.gov/36637424","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"33300617","id":"PMC_33300617","title":"How selective are clinical CDK4/6 inhibitors?","date":"2020","source":"Medicinal research reviews","url":"https://pubmed.ncbi.nlm.nih.gov/33300617","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32026294","id":"PMC_32026294","title":"The Utility of MDM2 and CDK4 Immunohistochemistry and MDM2 FISH in Craniofacial Osteosarcoma.","date":"2020","source":"Head and neck pathology","url":"https://pubmed.ncbi.nlm.nih.gov/32026294","citation_count":24,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"34087775","id":"PMC_34087775","title":"The role of CDK4/6 inhibitors in early breast cancer.","date":"2021","source":"Breast (Edinburgh, Scotland)","url":"https://pubmed.ncbi.nlm.nih.gov/34087775","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"32430489","id":"PMC_32430489","title":"Metabolic Adaptations to MEK and CDK4/6 Cotargeting in Uveal Melanoma.","date":"2020","source":"Molecular cancer therapeutics","url":"https://pubmed.ncbi.nlm.nih.gov/32430489","citation_count":23,"is_preprint":false,"source_track":"pubmed_title"},{"pmid":"8259215","id":"PMC_8259215","title":"A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4.","date":"1993","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8259215","citation_count":3482,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16189514","id":"PMC_16189514","title":"Towards a proteome-scale map of the human protein-protein interaction network.","date":"2005","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/16189514","citation_count":2090,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8078588","id":"PMC_8078588","title":"p15INK4B is a potential effector of TGF-beta-induced cell cycle arrest.","date":"1994","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/8078588","citation_count":1966,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"24390342","id":"PMC_24390342","title":"Genetics of rheumatoid arthritis contributes to biology and drug discovery.","date":"2013","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/24390342","citation_count":1778,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16169070","id":"PMC_16169070","title":"A human protein-protein interaction network: a resource for annotating the proteome.","date":"2005","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/16169070","citation_count":1704,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"12477932","id":"PMC_12477932","title":"Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.","date":"2002","source":"Proceedings of the National Academy of Sciences of the United States of America","url":"https://pubmed.ncbi.nlm.nih.gov/12477932","citation_count":1479,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9529249","id":"PMC_9529249","title":"ARF promotes MDM2 degradation and stabilizes p53: ARF-INK4a locus deletion impairs both the Rb and p53 tumor suppression pathways.","date":"1998","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/9529249","citation_count":1365,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9106657","id":"PMC_9106657","title":"New functional activities for the p21 family of CDK inhibitors.","date":"1997","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/9106657","citation_count":1269,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8449399","id":"PMC_8449399","title":"Direct binding of cyclin D to the retinoblastoma gene product (pRb) and pRb phosphorylation by the cyclin D-dependent kinase CDK4.","date":"1993","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8449399","citation_count":1214,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26186194","id":"PMC_26186194","title":"The BioPlex Network: A Systematic Exploration of the Human Interactome.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26186194","citation_count":1118,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"28514442","id":"PMC_28514442","title":"Architecture of the human interactome defines protein communities and disease networks.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/28514442","citation_count":1085,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"16109376","id":"PMC_16109376","title":"The bromodomain protein Brd4 is a positive regulatory component of P-TEFb and stimulates RNA polymerase II-dependent transcription.","date":"2005","source":"Molecular cell","url":"https://pubmed.ncbi.nlm.nih.gov/16109376","citation_count":1075,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"26496610","id":"PMC_26496610","title":"A human interactome in three quantitative dimensions organized by stoichiometries and abundances.","date":"2015","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/26496610","citation_count":1015,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"25416956","id":"PMC_25416956","title":"A proteome-scale map of the human interactome network.","date":"2014","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/25416956","citation_count":977,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7652577","id":"PMC_7652577","title":"A p16INK4a-insensitive CDK4 mutant targeted by cytolytic T lymphocytes in a human melanoma.","date":"1995","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/7652577","citation_count":939,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"29160310","id":"PMC_29160310","title":"Cyclin D-CDK4 kinase destabilizes PD-L1 via cullin 3-SPOP to control cancer immune surveillance.","date":"2017","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/29160310","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"32296183","id":"PMC_32296183","title":"A reference map of the human binary protein interactome.","date":"2020","source":"Nature","url":"https://pubmed.ncbi.nlm.nih.gov/32296183","citation_count":849,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"10499802","id":"PMC_10499802","title":"Cdk phosphorylation triggers sequential intramolecular interactions that progressively block Rb functions as cells move through G1.","date":"1999","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/10499802","citation_count":848,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8114739","id":"PMC_8114739","title":"Identification of G1 kinase activity for cdk6, a novel cyclin D partner.","date":"1994","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/8114739","citation_count":787,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8001816","id":"PMC_8001816","title":"Growth suppression by p18, a p16INK4/MTS1- and p14INK4B/MTS2-related CDK6 inhibitor, correlates with wild-type pRb function.","date":"1994","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8001816","citation_count":765,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"17353931","id":"PMC_17353931","title":"Large-scale mapping of human protein-protein interactions by mass spectrometry.","date":"2007","source":"Molecular systems biology","url":"https://pubmed.ncbi.nlm.nih.gov/17353931","citation_count":733,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939624","id":"PMC_22939624","title":"Quantitative analysis of HSP90-client interactions reveals principles of substrate recognition.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939624","citation_count":708,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"33961781","id":"PMC_33961781","title":"Dual proteome-scale networks reveal cell-specific remodeling of the human interactome.","date":"2021","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/33961781","citation_count":705,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"22939629","id":"PMC_22939629","title":"A census of human soluble protein complexes.","date":"2012","source":"Cell","url":"https://pubmed.ncbi.nlm.nih.gov/22939629","citation_count":689,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"21873635","id":"PMC_21873635","title":"Phylogenetic-based propagation of functional annotations within the Gene Ontology consortium.","date":"2011","source":"Briefings in bioinformatics","url":"https://pubmed.ncbi.nlm.nih.gov/21873635","citation_count":656,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8528263","id":"PMC_8528263","title":"Germline mutations in the p16INK4a binding domain of CDK4 in familial melanoma.","date":"1996","source":"Nature genetics","url":"https://pubmed.ncbi.nlm.nih.gov/8528263","citation_count":639,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"7739547","id":"PMC_7739547","title":"Novel INK4 proteins, p19 and p18, are specific inhibitors of the cyclin D-dependent kinases CDK4 and CDK6.","date":"1995","source":"Molecular and cellular biology","url":"https://pubmed.ncbi.nlm.nih.gov/7739547","citation_count":618,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"9311993","id":"PMC_9311993","title":"Phosphorylation-dependent degradation of the cyclin-dependent kinase inhibitor p27.","date":"1997","source":"The EMBO journal","url":"https://pubmed.ncbi.nlm.nih.gov/9311993","citation_count":602,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"8101826","id":"PMC_8101826","title":"Subunit rearrangement of the cyclin-dependent kinases is associated with cellular transformation.","date":"1993","source":"Genes & development","url":"https://pubmed.ncbi.nlm.nih.gov/8101826","citation_count":569,"is_preprint":false,"source_track":"gene2pubmed"},{"pmid":"15761153","id":"PMC_15761153","title":"High-throughput mapping of a dynamic signaling network in mammalian cells.","date":"2005","source":"Science (New York, N.Y.)","url":"https://pubmed.ncbi.nlm.nih.gov/15761153","citation_count":553,"is_preprint":false,"source_track":"gene2pubmed"}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":45380,"output_tokens":6629,"usd":0.117788},"stage2":{"model":"claude-opus-4-6","input_tokens":10311,"output_tokens":4477,"usd":0.24522},"total_usd":0.793274,"stage1_batch_id":"msgbatch_011kfMfE81o6CTcyhVUqumuW","stage2_batch_id":"msgbatch_01DTputS6WNkH745x1nVSoBo","note":"batch pricing = 50% of standard","round2_stage1":{"model":"claude-sonnet-4-6","input_tokens":57079,"output_tokens":9868,"usd":0.159629},"round2_rules_fired":"R3","round2_stage2":{"model":"claude-opus-4-6","input_tokens":14135,"output_tokens":4390,"usd":0.270637}},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2006,\n      \"finding\": \"Hsp90-Cdc37-Cdk4 form a stable ternary complex in which Cdc37 acts as a scaffold simultaneously binding Cdk4 and Hsp90; the 3D structure determined by single-particle electron microscopy reveals the locations of Cdc37 and Cdk4 within the complex and suggests that conformational changes in the kinase are coupled to the Hsp90 ATPase cycle.\",\n      \"method\": \"Purification of recombinant complex, native mass spectrometry (stoichiometry), single-particle electron microscopy with crystal-structure comparison\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted complex, structural determination with functional modeling, single rigorous study\",\n      \"pmids\": [\"16949366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CDK4 (in complex with D-type cyclin) is phosphorylated and enzymatically activated on Thr-172 by the CDK-activating kinase (CAK), whose catalytic subunit is p39MO15 assembled with cyclin H; CAK activity toward cyclin D-CDK4 is present constitutively throughout the cell cycle and in quiescent cells, indicating it is not rate-limiting for mitogen-driven G1 progression per se.\",\n      \"method\": \"In vitro kinase assays with recombinant proteins, immunodepletion of CAK from cell lysates with recovery in immune complexes, CAK immune-complex assay across cell cycle stages\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro activation assay with mutagenesis-equivalent biochemical dissection, replicated with multiple CDK substrates\",\n      \"pmids\": [\"7935441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cdk7 (metazoan CAK) is the activating kinase for Cdk4 and Cdk6 in human cells; unlike Cdk1/Cdk2 where phosphorylation is a one-time licensing event, Cdk7-mediated T-loop phosphorylation of Cdk4 is continuously required to maintain Cdk4 activity, and activating phosphorylation of Cdk7 rises concurrently with that of Cdk4 as cells exit quiescence, forming a CDK-activation cascade during G1.\",\n      \"method\": \"Chemical-genetic inhibition of Cdk7 (analog-sensitive allele), in vitro kinase assays, cell-cycle re-entry experiments with phospho-specific antibodies\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemical genetics plus in vitro reconstitution; mechanistically distinct from prior CAK studies\",\n      \"pmids\": [\"23622515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"p34(SEI-1) binds CDK4 and renders the cyclin D1-CDK4 complex resistant to inhibition by p16(INK4a), functioning as a growth factor-regulated activator of CDK4 that promotes cell proliferation even at inhibitory levels of INK4 proteins.\",\n      \"method\": \"Protein interaction assays (binding), kinase activity assays in presence of p16, serum-induction experiments, ectopic expression in fibroblasts\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal binding assay plus kinase activity rescue with defined molecular mechanism\",\n      \"pmids\": [\"10580009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"p19INK4d directly binds and inhibits CDK4 and CDK6 kinase activity but not other CDKs; unlike p21/p27 whose interaction with CDKs is stimulated by cyclin, p19INK4d binding to CDK6 is hindered by D-type cyclins, indicating that INK4 proteins and D cyclins compete for CDK4/6 in a mutually exclusive manner.\",\n      \"method\": \"Co-immunoprecipitation, in vitro kinase assays, competitive binding experiments with recombinant proteins\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with competition assays establishing mutually exclusive binding mechanism\",\n      \"pmids\": [\"8741839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"During myogenic differentiation of C2C12 cells, p18INK4c accumulates massively and sequentially associates first with CDK6 and then with CDK4; in terminally differentiated muscle, all CDK6 and half of CDK4 are complexed with p18, correlating with decreased CDK4 kinase activity and permanent cell cycle arrest.\",\n      \"method\": \"Co-immunoprecipitation, kinase activity assays, Western blotting during time-course of myogenesis\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — temporal co-IP with kinase assays across differentiation, replicated in vivo in muscle tissue\",\n      \"pmids\": [\"8898364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Combined genetic loss of Cdk2 and Cdk4 in mice causes embryonic lethality (~E15) with progressive reduction of Rb phosphorylation and decreased E2F-target gene expression; HPV-E7-mediated Rb inactivation rescues proliferation and senescence defects in double-KO MEFs, placing Cdk2/Cdk4 cooperatively upstream of Rb phosphorylation in vivo.\",\n      \"method\": \"Double-knockout mouse generation, MEF proliferation/senescence assays, Western blotting for Rb phosphorylation, epistasis rescue with E7 and p27 knockout\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis with multiple orthogonal rescues; replicated in vivo and in MEFs\",\n      \"pmids\": [\"16678773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"c-MYC transcriptionally activates CDK4 through four conserved E-box binding sites in the CDK4 promoter; c-MYC-deficient RAT1 cells show defective CDK4 induction and delayed cell-cycle re-entry, and ectopic CDK4 expression partially rescues this growth defect.\",\n      \"method\": \"SAGE, promoter-reporter assays with MYC binding site analysis, RT-PCR/Western blot in c-MYC null cells, rescue by CDK4 overexpression\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter binding validated, loss-of-function phenotype rescued by CDK4 re-expression\",\n      \"pmids\": [\"10688915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cyclin D1-CDK4 phosphorylates and activates the histone acetyltransferase GCN5 in hepatocytes in response to insulin, leading to increased acetylation of PGC-1α and suppression of hepatic gluconeogenesis independently of cell cycle progression; loss of hepatic cyclin D1 increases gluconeogenesis and causes hyperglycemia in mice.\",\n      \"method\": \"In vitro kinase assay (CDK4 phosphorylates GCN5), mouse liver conditional knockout, chemical screen for CDK4 inhibitors affecting PGC-1α acetylation, glucose tolerance tests\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay plus mouse genetic loss-of-function with defined metabolic phenotype; multiple orthogonal methods in a single study\",\n      \"pmids\": [\"24870244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"CDK4 activates E2F1 in pancreatic beta cells by phosphorylating pRB, and E2F1 directly occupies and activates the Kir6.2 (KCNJ11) promoter; CDK4 inhibition or E2F1 genetic loss reduces Kir6.2 expression, impairs glucose-induced insulin secretion, and causes glucose intolerance in mice.\",\n      \"method\": \"Chromatin immunoprecipitation (ChIP) from tissues, CDK4 inhibitor treatment of isolated islets, E2f1 knockout mice, Kir6.2 rescue experiments, glucose-stimulated insulin secretion assays\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP from tissues plus genetic rescue; multiple orthogonal readouts\",\n      \"pmids\": [\"19597485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDK4 directly phosphorylates AMPKα2 to inhibit its kinase activity, thereby promoting anaerobic glycolysis and repressing fatty acid oxidation (FAO); expression of non-phosphorylatable AMPKα2 mutants or CDK4 inhibition increases FAO in MEFs and myotubes, and Cdk4−/− mice show increased oxidative metabolism and exercise capacity.\",\n      \"method\": \"In vitro kinase assay (CDK4 phosphorylates AMPKα2), non-phosphorylatable mutant expression, Cdk4 knockout mice, metabolic flux measurements, AMPK muscle-specific knockout epistasis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro phosphorylation assay plus mutagenesis plus genetic epistasis in vivo\",\n      \"pmids\": [\"29053957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cyclin D-CDK4/6 complexes phosphorylate CDC25A on Ser40 during G1 phase, promoting CDC25A ubiquitination by βTrCP and proteasomal degradation, constituting a negative feedback loop that controls the G1/S transition.\",\n      \"method\": \"In vitro kinase assay with recombinant CyclinD-CDK4/6, phospho-mutant CDC25A constructs, βTrCP knockdown, stability assays\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro phosphorylation plus mutagenesis plus E3 ligase epistasis\",\n      \"pmids\": [\"28192398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK4 phosphorylates folliculin (FLCN) to regulate mTORC1 recruitment to the lysosomal surface in response to amino acids; additionally, CDK4 is required for lysosomal degradative function, and its loss causes accumulation of undigested material, impaired autophagic flux, and cancer cell senescence.\",\n      \"method\": \"In vitro CDK4 kinase assay on FLCN, CDK4 pharmacological inhibition and genetic inactivation, lysosomal fractionation, autophagic flux assays, xenograft models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct kinase-substrate assay plus genetic loss-of-function with defined organellar phenotype\",\n      \"pmids\": [\"31395606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"FKBP5 (a peptidyl-prolyl isomerase) sequesters CDK4 within the Hsp90 storage complex, preventing cyclin D1-CDK4 complex formation; separately, FKBP5 promotes cis-trans isomerization of the Thr172-Pro173 peptide bond in CDK4, inhibiting Thr172 phosphorylation (the activating modification) and thereby blocking CDK4 activation during myoblast differentiation.\",\n      \"method\": \"Co-immunoprecipitation, in vitro isomerization assay, phospho-Thr172 Western blotting, Fkbp5 knockout mouse muscle regeneration, comparison with FKBP4\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — biochemical isomerization assay plus genetic knockout phenotype; novel mechanism with structural specificity demonstrated\",\n      \"pmids\": [\"30485818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Knock-in mice expressing CDK4-R24C (the p16INK4a-insensitive familial melanoma mutation) are highly susceptible to melanoma after carcinogenic treatment; these tumors lack p19ARF/p53 pathway mutations, placing the p16INK4a-CDK4-Rb pathway as the specific tumor-suppressive axis in melanoma, and p18INK4c but not p15INK4b deletion cooperates with CDK4-R24C.\",\n      \"method\": \"Knock-in mouse model, carcinogen treatment, tumor histology, mutation analysis, INK4 compound mutant mice\",\n      \"journal\": \"Proceedings of the National Academy of Sciences of the United States of America\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis in vivo with pathway placement via compound mutants\",\n      \"pmids\": [\"11606789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"STAT1 directly interacts with the cyclin D1/CDK4 complex; IFN-γ-induced STAT1 (via its Ser727 phosphorylation, not Tyr701) promotes proteasomal degradation of cyclin D1, reducing CDK4-mediated pRb phosphorylation and thereby mediating G1 cell cycle arrest.\",\n      \"method\": \"Co-immunoprecipitation of STAT1 with cyclin D1 and CDK4, phospho-mutant STAT1 constructs, proteasome inhibitor rescue, STAT1-deficient cell analysis, pRb phosphorylation Western blotting\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct binding demonstrated with mechanistic mutants, single lab study\",\n      \"pmids\": [\"21084836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK4 binding by CDKN2A (p16INK4a) and related INK4 family proteins physically occludes palbociclib (CDK4/6 inhibitor) target engagement; in cells with functional CDKN2A, palbociclib fails to engage CDK4, explaining context-dependent drug insensitivity.\",\n      \"method\": \"Chemo-proteomics (competitive activity-based probe), isogenic cell lines with engineered CDKN2A status, panel of characterized cell lines\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemo-proteomic target engagement assay with isogenic controls; mechanistically defines how INK4 proteins gate drug access\",\n      \"pmids\": [\"30837298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"INK4 proteins (e.g., p18INK4C) induced by CDK6 upregulation form a p18INK4C-cyclin D-CDK6 ternary complex that occludes CDK4/6 inhibitor (palbociclib) binding while only weakly suppressing ATP binding, conferring resistance to CDK4/6 inhibitors; suppression of INK4 expression or its binding to CDK6 restores drug sensitivity.\",\n      \"method\": \"In vitro binding assays, in vitro kinase assays, physical modeling, genetic suppression of INK4 proteins, survey of >1,300 breast cancer genomic alterations\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with binding and kinase assays plus structural modeling; mechanistically explains resistance\",\n      \"pmids\": [\"34544752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"CDK4 activity is required for centrosome amplification and binucleation in HER2-positive breast cancer cells; CDK4 knockdown normalizes cytokinesis and reduces centrosome numbers, and a functional connection exists between CDK4 and Nek2 protein levels (each knockdown reduces the other), suggesting Cdk4-Nek2 signaling drives centrosome amplification.\",\n      \"method\": \"siRNA knockdown of CDK4 and Nek2, centrosome counting, cytokinesis imaging, Western blotting for Nek2 levels upon CDK4 depletion\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — single lab, loss-of-function with specific phenotypic readout but mechanism (direct vs indirect Nek2 regulation) not fully resolved\",\n      \"pmids\": [\"23776583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK4/6 activity increases rapidly before CDK2 in G1; stress signals can rapidly inactivate CDK4/6 to return cells to quiescence, but this probability decreases as cells approach S phase, indicating CDK4/6 activity persistence increases progressively in G1 to restrict quiescence re-entry.\",\n      \"method\": \"Fluorescent reporter system for simultaneous real-time CDK4/6 and CDK2 activity monitoring in single living cells, stress signal perturbation experiments\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live single-cell reporters with functional consequence; reveals ordered CDK4/6→CDK2 activation cascade\",\n      \"pmids\": [\"32255427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"The CDK4/CDK6 inhibitor PD0332991 (palbociclib) inhibits the phosphorylation and activity of p21-bound cyclin D-CDK4/6 complexes, but paradoxically stabilizes activated cyclin D3-CDK4/6 complexes devoid of p21/p27; after drug washout these persistently activated complexes drive unexpected cell cycle entry in the absence of mitogenic stimulation.\",\n      \"method\": \"Cell cycle analysis, phospho-CDK4 and p21 co-immunoprecipitation, drug washout experiments, Western blotting\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic distinction between p21-bound and p21-free CDK4 complexes with defined functional outcome; single lab study\",\n      \"pmids\": [\"25486476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDK4/6 inhibitors activate expression of endogenous retroviral elements in tumor cells, increasing intracellular double-stranded RNA, stimulating type III interferon production and enhancing tumor antigen presentation; separately, CDK4/6 inhibitors suppress regulatory T cell proliferation through reduced activity of the E2F target DNMT1.\",\n      \"method\": \"Mouse breast carcinoma models, transcriptomic analysis of serial clinical biopsies, DNMT1 activity assays, flow cytometry of immune populations, dsRNA quantification\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple orthogonal mechanistic readouts across mouse models and clinical samples; highly cited and replicated conceptually\",\n      \"pmids\": [\"28813415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK4 phosphorylates EZH2 in keratinocytes, triggering EZH2-mediated STAT3 methylation and activation, which induces IκBζ and proinflammatory cytokine synthesis relevant to psoriasis; pharmacological or genetic inhibition of CDK4/6 abrogates this pathway and prevents psoriasis in mouse models.\",\n      \"method\": \"Pathway delineation by genetic knockdown and inhibitor studies, phospho-EZH2 and STAT3 assays, CDK4/6 inhibitor topical application in mouse psoriasis models, ChIP for IκBζ promoter\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — multiple inhibitor/genetic combinations establishing CDK4→EZH2→STAT3→IκBζ axis, but direct in vitro CDK4 kinase assay on EZH2 not explicitly described\",\n      \"pmids\": [\"32701505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CDK4 activity determines the cell size threshold required for G1/S transition; CDK4 and p38 MAPK cooperate analogously to a thermostat—p38 senses when cells are smaller than target size (restricting cell cycle), while CDK4 sets the target size at which p38 is inactivated to allow cycle progression.\",\n      \"method\": \"CDK4 inhibitor and overexpression experiments, p38 activity reporter, cell size measurements, epistasis between CDK4 and p38 in size checkpoint\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — functional epistasis with quantitative size-checkpoint readouts; single lab study\",\n      \"pmids\": [\"34022133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"TRIM28 binds and promotes ubiquitination and proteasomal degradation of CDK4/6-phosphorylated RB protein; SETDB1, via its Tudor domain binding to methylated RB (independently of SETDB1 methyltransferase activity), protects phosphorylated RB from TRIM28-mediated degradation.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assays, SETDB1 Tudor domain mutants, pRb degradation assays, CDK4/6 inhibitor rescue experiments\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection with domain-specific mutants and multiple binding/degradation assays establishing CDK4/6-TRIM28-SETDB1 RB stability axis\",\n      \"pmids\": [\"36637424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"HR+ breast cancer cells are highly CDK4-dependent but not CDK6-dependent for proliferation, whereas human bone marrow hematopoietic cells rely primarily on CDK6; selective CDK4 inhibition (atirmociclib/PF-07220060) reduces neutropenia proportional to its CDK4 vs CDK6 selectivity while achieving deeper antitumor responses than dual CDK4/6 inhibitors.\",\n      \"method\": \"CDK4-selective inhibitor development, in vivo mouse models, dose-intensification studies, CDK4 vs CDK6 biochemical selectivity assays, bone marrow cell assays\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of CDK4 vs CDK6 tissue-specific dependency using selective inhibitor and in vivo models\",\n      \"pmids\": [\"40068598\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDK4 is a serine/threonine kinase that, upon T-loop phosphorylation at Thr172 by Cdk7 (CAK), forms active complexes with D-type cyclins to phosphorylate and inactivate the retinoblastoma protein (Rb), releasing E2F transcription factors to drive G1→S cell cycle progression; its activity is regulated by INK4 inhibitors (p16/p18/p19) competing with cyclins for CDK4 binding, by p21/p27 (which stabilize but modulate cyclin D-CDK4 complexes), by Hsp90-Cdc37 chaperoning, by FKBP5-mediated prolyl isomerization of Thr172-Pro173, and by SEI-1 which renders CDK4 resistant to INK4 inhibition; beyond the cell cycle, CDK4 directly phosphorylates substrates including GCN5 (controlling PGC-1α acetylation and hepatic gluconeogenesis), AMPKα2 (repressing fatty acid oxidation), FLCN (regulating lysosomal mTORC1), CDC25A (controlling its stability via βTrCP), and EZH2 (activating proinflammatory STAT3 signaling), and CDK4/6 inhibitors additionally promote anti-tumor immunity by inducing endogenous retroviral element expression and suppressing regulatory T cells through DNMT1.\"\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 1993,\n      \"finding\": \"p16 (INK4a) binds directly to CDK4 and inhibits the catalytic activity of CDK4/cyclin D complexes, acting in a regulatory feedback circuit with CDK4, D-type cyclins, and retinoblastoma protein.\",\n      \"method\": \"Biochemical binding assays, kinase inhibition assays, cDNA isolation\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro kinase inhibition assay, foundational discovery replicated extensively\",\n      \"pmids\": [\"8259215\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"CDK4 in complex with D-type cyclins phosphorylates the retinoblastoma protein (pRb) at sites identical to those phosphorylated in human T cells; only D-type cyclins activate CDK4 enzyme activity; cyclin D2/D3 (but not D1) bind pRb directly; CDK4/cyclin D complexes phosphorylate pRb and release E2F-1.\",\n      \"method\": \"Baculovirus/Sf9 reconstitution, in vitro kinase assay, co-immunoprecipitation, pRb fusion protein phosphorylation\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted in vitro with multiple orthogonal methods, foundational study\",\n      \"pmids\": [\"8449399\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1993,\n      \"finding\": \"In SV40-transformed cells, CDK4 dissociates from cyclin D, PCNA, and p21 and instead associates exclusively with a 16 kDa protein (p16), demonstrating subunit rearrangement of CDK4 complexes is associated with cellular transformation.\",\n      \"method\": \"Co-immunoprecipitation, biochemical fractionation of normal vs. transformed fibroblasts\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — reciprocal co-IP, replicated across multiple transformation models\",\n      \"pmids\": [\"8101826\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CDK4/cyclin D complexes require phosphorylation on Thr-172 for enzymatic activation; this step is catalyzed by CAK (cdk-activating kinase, p39MO15/cyclin H complex), which can phosphorylate and activate both cdk2 and cdk4 in their respective cyclin complexes.\",\n      \"method\": \"In vitro kinase assay, immune-depletion, baculovirus reconstitution with p39MO15 and cyclin H\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro reconstitution with activating phosphorylation assay and immune-depletion validation\",\n      \"pmids\": [\"7935441\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"p21(CIP), p27(KIP), and p57(KIP2) promote the assembly of CDK4 with D-type cyclins; at low concentrations p21 promotes active CDK4/cyclin D complex formation, and most cellular CDK4/cyclin D kinase activity co-associates with p21; CIP/KIP proteins also target CDK4 and cyclin D1 to the nucleus.\",\n      \"method\": \"In vitro assembly assays, kinetic analyses (K_a, K_off measurements), immunodepletion, subcellular fractionation\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — quantitative in vitro assembly kinetics plus in vivo immunodepletion, multiple orthogonal methods\",\n      \"pmids\": [\"9106657\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"p15INK4B, a new member of the p16 family induced ~30-fold by TGF-β in human keratinocytes, inhibits CDK4 and CDK6, identifying it as a potential effector of TGF-β-mediated G1 cell cycle arrest.\",\n      \"method\": \"cDNA isolation, TGF-β induction assay, CDK4/6 kinase inhibition assay\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct kinase inhibition demonstrated, TGF-β induction linked mechanistically\",\n      \"pmids\": [\"8078588\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"CDK6 (PLSTIRE gene product) is activated by D-type cyclins and phosphorylates pRb during mid-G1, analogous to CDK4.\",\n      \"method\": \"Sf9 baculovirus co-expression, in vitro kinase assay, co-immunoprecipitation\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstituted activity in insect cells, pRb phosphorylation confirmed\",\n      \"pmids\": [\"8114739\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"p18 (INK4C) interacts strongly with CDK6 and weakly with CDK4, inhibits cyclin D-CDK6 kinase activity, and forms binary (not ternary) complexes with CDK4/CDK6, competing with cyclin binding; growth suppression by p18 correlates with wild-type pRb function.\",\n      \"method\": \"Yeast two-hybrid, in vitro binding, kinase inhibition assay, growth suppression in NIH 3T3 cells\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — multiple orthogonal methods including in vitro kinase assay and genetic growth suppression assay\",\n      \"pmids\": [\"8001816\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1994,\n      \"finding\": \"A 15-kDa CDK-binding protein (p15cdk-BP) specifically binds CDK4/cyclin D and CDK5, but not CDC2 or CDK2, identifying a distinct CDK4-selective binding partner.\",\n      \"method\": \"Affinity chromatography (p15cdk-BP-Sepharose), anti-CDK antibody Western blotting, phosphopeptide mapping\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — affinity pulldown with multiple CDK specificity controls\",\n      \"pmids\": [\"8175758\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"A CDK4 R24C point mutation (arginine-to-cysteine at residue 24) found in human melanoma prevents binding of p16INK4a (but not p21 or p27KIP1), rendering CDK4 insensitive to this tumor suppressor; the mutant peptide is recognized as a tumor-specific antigen by cytolytic T lymphocytes.\",\n      \"method\": \"Mutant CDK4 sequencing from melanoma tissue, p16/p21/p27 binding assay, CTL recognition assay\",\n      \"journal\": \"Science\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — direct binding assay with multiple inhibitors, confirmed in tumor tissue and CTL assay\",\n      \"pmids\": [\"7652577\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1995,\n      \"finding\": \"Mouse p19 (INK4D) and p18 (INK4C) specifically inhibit CDK4 and CDK6 kinase activities but not CDK2, CDC2; they bind CDK4/CDK6 directly (in or out of cyclin D complexes) and can displace cyclin D from CDK4/6 in vivo, inducing G1 arrest.\",\n      \"method\": \"In vitro kinase inhibition assay, co-immunoprecipitation, retroviral overexpression, cell cycle analysis\",\n      \"journal\": \"Molecular and cellular biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro kinase inhibition plus in vivo genetic assay\",\n      \"pmids\": [\"7739547\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"p19INK4D is a specific inhibitor of CDK4 and CDK6; it interacts with both kinases (independently of cyclins) and inhibits their activity; interaction with CDK4/CDK6 is hindered by the cyclin subunit, and binary cyclin D–p19 or cyclin D–CDK6 complexes are mutually exclusive, suggesting INK4 proteins and D cyclins compete for CDK4/6 binding.\",\n      \"method\": \"Yeast two-hybrid, co-immunoprecipitation, kinase inhibition assay, chromosome mapping\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — multiple binding/inhibition assays, competition demonstrated biochemically\",\n      \"pmids\": [\"8741839\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"During myogenic differentiation, p18INK4C protein increases 50-fold and sequentially associates first with CDK6 then with CDK4, with all CDK6 and half of CDK4 complexed with p18 in terminally differentiated muscle; CDK4 kinase activity decreases during differentiation, supporting p18 as critical for maintaining permanent cell cycle arrest in muscle.\",\n      \"method\": \"Co-immunoprecipitation, Western blot, kinase activity assay in C2C12 cells and adult mouse muscle\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — kinase assay plus co-IP across differentiation time course in two biological contexts\",\n      \"pmids\": [\"8898364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Random mutagenesis of p16INK4a reveals that multiple residues throughout the entire gene are important for binding to CDK4, with no single mutational hot spot; mutations reducing binding also severely affect kinase-inhibitory activity.\",\n      \"method\": \"Random mutagenesis, yeast two-hybrid binding assay, kinase inhibition assay\",\n      \"journal\": \"Biochemical and biophysical research communications\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — systematic mutagenesis screen with binding and functional assays\",\n      \"pmids\": [\"8573142\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1996,\n      \"finding\": \"Germline CDK4 R24C (and R24H) mutations in the p16INK4a-binding domain cause familial melanoma susceptibility.\",\n      \"method\": \"Germline mutation sequencing in familial melanoma kindreds\",\n      \"journal\": \"Nature genetics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic epistasis confirmed in multiple melanoma families, functionally linked to p16 binding domain\",\n      \"pmids\": [\"8528263\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1997,\n      \"finding\": \"ARF (p19ARF) binds to MDM2 and promotes its degradation, stabilizing p53; deletion of the INK4a-ARF locus simultaneously impairs both the p16INK4a-cyclin D/CDK4-Rb and ARF-MDM2-p53 tumor suppression pathways.\",\n      \"method\": \"Co-immunoprecipitation, MDM2 degradation assay, G1 arrest rescue experiment\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — mechanistic dissection of two tumor suppressor pathways with biochemical and cell-based assays\",\n      \"pmids\": [\"9529249\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"CDK4 T172 phosphorylation in the T-loop is a critical activating modification; the novel CDK4-binding protein p34(SEI-1) antagonizes p16INK4a by rendering cyclin D1-CDK4 resistant to p16INK4a inhibition, and SEI-1 expression is induced by serum stimulation, facilitating cyclin D-CDK complex formation.\",\n      \"method\": \"In vitro kinase assay, p16 competition binding assay, serum induction experiment, ectopic expression in fibroblasts\",\n      \"journal\": \"Genes & development\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical reconstitution of p16 resistance plus cellular proliferation assay\",\n      \"pmids\": [\"10580009\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 1999,\n      \"finding\": \"Sequential CDK4/6-dependent phosphorylation of the Rb C-terminal region initiates intramolecular interactions that displace histone deacetylase from the Rb pocket, blocking active transcriptional repression; subsequent CDK2-mediated pocket phosphorylation disrupts pocket structure and releases E2F, providing a molecular basis for ordered Rb inactivation during G1.\",\n      \"method\": \"In vitro phosphorylation assays, mutant Rb constructs, co-immunoprecipitation, HDAC binding assays\",\n      \"journal\": \"Cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — reconstitution with defined mutants, multiple orthogonal assays, mechanistically detailed\",\n      \"pmids\": [\"10499802\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2000,\n      \"finding\": \"c-MYC transcriptionally activates CDK4 via four conserved MYC binding sites in the CDK4 promoter; c-MYC-deficient RAT1 cells show delayed cell cycle progression associated with defective CDK4 induction, and ectopic CDK4 expression partially rescues this growth defect.\",\n      \"method\": \"Serial analysis of gene expression (SAGE), promoter binding/transcription assay, c-MYC-deficient cell rescue experiment\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — promoter binding demonstrated, genetic rescue with ectopic CDK4 confirms pathway placement\",\n      \"pmids\": [\"10688915\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2001,\n      \"finding\": \"Knock-in mice expressing the CDK4 R24C allele (insensitive to INK4 inhibition) are highly susceptible to melanoma development; these tumors lack p19ARF/p53 mutations, indicating the p16INK4a/CDK4/Rb pathway is specifically involved in melanoma. Deletion of p18INK4C (but not p15INK4B) confers additional proliferative advantage, establishing a functional hierarchy of INK4 proteins on CDK4 in melanocytes.\",\n      \"method\": \"Knock-in mouse model, carcinogen treatment, tumor sequencing, genetic epistasis with INK4 knockouts\",\n      \"journal\": \"PNAS\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis with multiple INK4 knockouts, pathway-specific tumor suppressor dissection\",\n      \"pmids\": [\"11606789\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Single-particle electron microscopy of a reconstituted Hsp90-Cdc37-Cdk4 complex defines its 3D structure and stoichiometry; Cdc37 acts as a scaffold simultaneously binding Cdk4 and Hsp90, and conformational changes in Cdk4 are coupled to the Hsp90 ATPase cycle.\",\n      \"method\": \"Reconstitution and purification of ternary complex, single-particle EM, stoichiometry determination, comparison with Hsp90 crystal structure\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — structural determination with reconstituted complex and mechanistic coupling analysis\",\n      \"pmids\": [\"16949366\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"Combined loss of Cdk2 and Cdk4 in mice causes embryonic lethality (~E15) with heart defects, progressive decline in Rb phosphorylation, reduced E2F-target gene expression, and premature senescence in MEFs; HPV-E7 inactivation of Rb rescues these defects, demonstrating Cdk2 and Cdk4 cooperate to phosphorylate Rb in vivo and couple G1/S transition to mitosis via E2F.\",\n      \"method\": \"Double knockout mice, Rb phosphorylation assay, E2F target gene expression, HPV-E7 rescue, p27 knockout epistasis\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — genetic double knockout with multiple epistasis rescue experiments\",\n      \"pmids\": [\"16678773\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"T-loop phosphorylation of CDK4 (but not CDK6) at Thr172 is a determining target for cell cycle control by extracellular factors; CDK4's subcellular location and association with D-type cyclins are regulated by mitogenic/antimitogenic signals.\",\n      \"method\": \"Biochemical analysis of CDK4 T172 phosphorylation in response to extracellular signals, subcellular fractionation, comparison with CDK6\",\n      \"journal\": \"Cell division\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — phosphorylation-specific analysis with extracellular signal linkage, single lab review synthesis\",\n      \"pmids\": [\"17092340\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"The CDK4-pRB-E2F1 pathway controls insulin secretion in pancreatic β-cells by regulating expression of Kir6.2 (a K-ATP channel component); glucose activates CDK4 via the insulin/GSK-3β pathway, leading to E2F1 activation and increased Kir6.2 expression; CDK4 inhibition or E2F1 knockout impairs insulin secretion and causes glucose intolerance in mice.\",\n      \"method\": \"Chromatin immunoprecipitation from tissues, CDK4 inhibitor treatment, E2f1−/− mouse phenotype, Kir6.2 rescue experiment\",\n      \"journal\": \"Nature cell biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — ChIP from tissues, genetic knockout, pharmacologic inhibition, and rescue assay\",\n      \"pmids\": [\"19597485\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2010,\n      \"finding\": \"STAT1 directly interacts with the cyclin D1/CDK4 complex; IFN-γ activates STAT1 (via Ser727 phosphorylation), which interacts with cyclin D1 to promote its proteasomal degradation, reducing Rb phosphorylation and inducing G1 arrest independently of STAT1 transcriptional activity.\",\n      \"method\": \"Co-immunoprecipitation, STAT1 point mutant analysis, proteasome inhibitor treatment, STAT1-deficient cell comparison\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — co-IP plus genetic (STAT1-deficient cells) and pharmacologic (proteasome inhibitor) validation\",\n      \"pmids\": [\"21084836\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cdk7 is a Cdk4- and Cdk6-activating kinase in human cells, required to maintain (not just establish) Cdk4 activity; Cdk7 activating phosphorylation rises concurrently with Cdk4 activating phosphorylation as cells exit quiescence, and Cdk7 accelerates Cdk4 activation in vitro, establishing a CDK-activation cascade during G1 progression.\",\n      \"method\": \"Chemical genetics (analog-sensitive Cdk7), in vitro Cdk4 activation assay, cell quiescence/exit experiments, phosphorylation time course\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — chemical genetic dissection plus in vitro activation assay with quiescence rescue\",\n      \"pmids\": [\"23622515\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2013,\n      \"finding\": \"Cdk4 loss abrogates centrosome amplification and binucleation in HER2+ breast cancer cells; Nek2 protein levels decrease upon Cdk4 knockdown and vice versa, indicating a molecular connection whereby Cdk4 signals centrosome amplification through Nek2, and defective cytokinesis (normalized by Cdk4 downregulation) is the source of binucleation.\",\n      \"method\": \"shRNA knockdown, Nek2 overexpression, centrosome/cell cycle analysis in HER2+ cell lines\",\n      \"journal\": \"PloS one\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 3 — knockdown and reciprocal expression analysis, single lab\",\n      \"pmids\": [\"23776583\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Cyclin D1-CDK4 phosphorylates and activates GCN5 acetyltransferase, which then acetylates and inhibits PGC-1α activity on gluconeogenic genes, thereby suppressing hepatic glucose production independently of cell cycle progression; insulin/GSK-3β signaling stabilizes nuclear cyclin D1, and dietary amino acids increase hepatic cyclin D1 mRNA.\",\n      \"method\": \"Cell-based high-throughput chemical screen, in vitro kinase assay (CDK4 phosphorylating GCN5), PGC-1α acetylation assay, Cdk4−/− mouse metabolic phenotype, Cdk4 inhibitor treatment\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — in vitro kinase assay demonstrating direct GCN5 phosphorylation, multiple genetic and pharmacologic validations\",\n      \"pmids\": [\"24870244\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"PD0332991 (palbociclib) inhibits CDK4/6 activity but paradoxically stabilizes activated cyclin D3-CDK4/6 complexes that are devoid of p21/p27; the inhibitor has opposite effects on p21-bound versus p21-free CDK4/6 complexes, and stabilized activated complexes persist for ≥24 h after drug removal, causing paradoxical cell cycle entry without mitogenic stimulation.\",\n      \"method\": \"CDK4/6 complex purification, phosphorylation state analysis, cell cycle assay after drug washout\",\n      \"journal\": \"Cell cycle\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — biochemical dissection of p21-bound vs. p21-free complexes with functional cell cycle consequence\",\n      \"pmids\": [\"25486476\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDK4 directly phosphorylates AMPKα2 to inhibit its activity, thereby repressing fatty acid oxidation and promoting anaerobic glycolysis; Cdk4−/− mice have increased oxidative metabolism and exercise capacity, and CDK4 inhibition mimics this metabolic shift in an AMPK-dependent manner in skeletal muscle.\",\n      \"method\": \"In vitro kinase assay (CDK4 phosphorylating AMPKα2), non-phosphorylatable AMPKα2 mutants, CDK4 inhibitor treatment, Cdk4−/− mouse exercise phenotype, AMPK-deficient muscle epistasis\",\n      \"journal\": \"Molecular cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro phosphorylation plus mutagenesis and in vivo genetic epistasis\",\n      \"pmids\": [\"29053957\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Cyclin D-CDK4 phosphorylates SPOP (speckle-type POZ protein), promoting SPOP degradation via FZR1/APC; this stabilizes PD-L1 protein. When CDK4/6 is inhibited, SPOP degradation is prevented, enabling SPOP to ubiquitinate PD-L1 via cullin 3 for proteasomal degradation, thus reducing PD-L1 levels and increasing tumor-infiltrating lymphocytes.\",\n      \"method\": \"In vitro CDK4 kinase assay on SPOP, co-immunoprecipitation, ubiquitination assay, CDK4/6 inhibitor treatment in vivo, SPOP loss-of-function mutations in tumors\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro kinase assay, ubiquitination reconstitution, in vivo mouse validation\",\n      \"pmids\": [\"29160310\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CDK4/6 inhibitors activate tumor cell expression of endogenous retroviral elements, increasing intracellular double-stranded RNA and stimulating type III interferon production; CDK4/6 inhibitors also markedly suppress regulatory T cell proliferation; both effects involve reduced activity of the E2F target DNMT1, promoting anti-tumor immunity.\",\n      \"method\": \"Mouse tumor models, transcriptomic analysis of clinical trial biopsies, regulatory T cell proliferation assay, dsRNA/IFN measurement\",\n      \"journal\": \"Nature\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple mechanistic arms tested in preclinical models and clinical specimens\",\n      \"pmids\": [\"28813415\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CyclinD/Cdk4 phosphorylates TSC1/2 in Drosophila wing disc cells at the G1/S transition, activating TORC1; this reveals a conserved mechanism linking cell cycle progression to nutrient sensing via Cdk4.\",\n      \"method\": \"In situ TORC1 activity readout (anti-phospho-dRpS6 antibody), genetic epistasis in Drosophila wing disc, CycD/Cdk4 overexpression\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — in vivo genetic epistasis in Drosophila with novel TORC1 activity reporter; ortholog findings consistent with mammalian CDK4\",\n      \"pmids\": [\"28829945\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"CyclinD1-CDK4 directly phosphorylates CDC25A on Ser40 during G1, promoting CDC25A degradation in a βTrCP-dependent manner, thus generating a negative feedback loop controlling the G1/S transition.\",\n      \"method\": \"In vitro kinase assay (cyclin D1-CDK4 on CDC25A), phosphorylation mapping (Ser40), βTrCP-dependent stability assay, cell cycle synchrony\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 — direct in vitro kinase assay with site identification and degradation mechanism\",\n      \"pmids\": [\"28192398\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"CDK4/6 phosphorylates EZH2 in keratinocytes, triggering EZH2-mediated methylation-induced STAT3 activation; active STAT3 induces IκBζ, a proinflammatory transcription factor required for cytokine synthesis in psoriasis; pharmacological or genetic inhibition of CDK4/6 or EZH2 suppresses IκBζ and psoriatic gene expression.\",\n      \"method\": \"In vitro CDK4/6 kinase assay on EZH2, STAT3 methylation/activation assay, CDK4/6i and EZH2i treatment in keratinocytes and mouse psoriasis models\",\n      \"journal\": \"The Journal of clinical investigation\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct kinase assay, downstream signaling pathway dissection, in vivo mouse model validation\",\n      \"pmids\": [\"32701505\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"Fkbp5 promotes myoblast differentiation through two CDK4-specific mechanisms: (1) it sequesters CDK4 within the Hsp90 storage complex, preventing cyclin D1-CDK4 complex formation; (2) it promotes cis-trans isomerization of the Thr172-Pro173 peptide bond in CDK4, inhibiting Thr172 phosphorylation (required for CDK4 activation). Fkbp5−/− mice show delayed muscle regeneration.\",\n      \"method\": \"Co-immunoprecipitation, peptidyl prolyl isomerization assay, Thr172 phosphorylation assay, Fkbp5−/− mouse muscle regeneration, comparison with Fkbp4\",\n      \"journal\": \"Cell reports\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — novel isomerization mechanism demonstrated biochemically with genetic in vivo validation\",\n      \"pmids\": [\"30485818\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK4 phosphorylates folliculin (FLCN), regulating mTORC1 recruitment to the lysosomal surface in response to amino acids; CDK4 also directly regulates lysosomal function and is essential for lysosomal degradation, thereby regulating mTORC1 activity; CDK4 loss leads to lysosomal dysfunction, impaired autophagic flux, and cancer cell senescence.\",\n      \"method\": \"In vitro CDK4 kinase assay on FLCN, lysosomal function assays, mTORC1 recruitment imaging, CDK4 inhibitor and genetic inactivation in xenograft models\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — direct substrate phosphorylation assay, lysosomal functional assay, in vivo xenograft validation\",\n      \"pmids\": [\"31395606\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2019,\n      \"finding\": \"CDK4 interaction with CDKN2A (p16INK4a family proteins) in cells prevents palbociclib from engaging CDK4; high CDKN2A causes drug insensitivity by occupying CDK4 before the inhibitor can bind, as shown by chemo-proteomics target engagement profiling in isogenic cells.\",\n      \"method\": \"Chemo-proteomics (activity-based protein profiling), isogenic cell lines with engineered CDKN2A levels, CDK4 target engagement assay\",\n      \"journal\": \"Molecular cancer therapeutics\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — chemo-proteomics with isogenic controls, direct target engagement quantification\",\n      \"pmids\": [\"30837298\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"CDK4/6 activity increases rapidly before CDK2 activity during cell cycle entry; stress signals in G1 can rapidly inactivate CDK4/6 to return cells to quiescence with decreasing probability as cells approach S phase, revealing CDK4/6 as the primary G1 activity determining quiescence exit timing and G1 length.\",\n      \"method\": \"Single-cell CDK4/6 and CDK2 activity reporter system (live imaging), stress signal perturbations\",\n      \"journal\": \"eLife\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — live-cell single-cell reporters with direct functional consequence measurement\",\n      \"pmids\": [\"32255427\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CDK4-dependent activation of p38 MAPK determines cell size homeostasis; CDK4 activity sets the target size threshold at which p38 is inactivated to permit cell cycle progression, functioning analogously to a thermostat dial for cell size.\",\n      \"method\": \"CDK4 inhibition/activation experiments, p38 activity assays, cell size measurements, genetic perturbations\",\n      \"journal\": \"Developmental cell\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 — direct functional link between CDK4 activity and p38 activation in defined cell size context\",\n      \"pmids\": [\"34022133\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"CDK6 upregulation confers resistance to CDK4/6 inhibitors by inducing and binding INK4 proteins (e.g., p18INK4C); the p18INK4C-cyclin D-CDK6 ternary complex occludes CDK4/6 inhibitor (palbociclib) binding while only weakly suppressing ATP binding, as shown by in vitro binding and kinase assays with physical modeling.\",\n      \"method\": \"In vitro binding assay, kinase assay, chemo-proteomics, physical modeling, PROTAC degrader development\",\n      \"journal\": \"Cancer discovery\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — biochemical binding/kinase assays, structural modeling, PROTAC validation in vivo\",\n      \"pmids\": [\"34544752\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SETDB1 protects CDK4/6-phosphorylated RB (p-RB) from degradation; TRIM28 binds and promotes ubiquitination and proteasomal degradation of CDK4/6-phosphorylated RB; SETDB1 (via its Tudor domain binding to methylated RB, independent of methyltransferase activity) opposes TRIM28 to stabilize p-RB, identifying a CDK4/6-dependent, TRIM28-mediated RB inactivation mechanism.\",\n      \"method\": \"Co-immunoprecipitation, ubiquitination assay, SETDB1 Tudor domain mutant analysis, antisense oligonucleotide, palbociclib combination in vivo\",\n      \"journal\": \"Cancer research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 — multiple biochemical assays, domain mutant analysis, in vivo validation\",\n      \"pmids\": [\"36637424\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"Selective CDK4 inhibition (atirmociclib/PF-07220060) shows reduced neutropenia compared to dual CDK4/6 inhibitors because CDK4 is dispensable for hematopoiesis (where CDK6 dominates), while HR+ breast cancer cells are highly CDK4-dependent; greater CDK4 target coverage leads to deeper anti-tumor responses.\",\n      \"method\": \"Selective CDK4 inhibitor development, neutrophil toxicity assays, CDK4 vs. CDK6 selectivity profiling, HR+ breast cancer cell line sensitivity, in vivo tumor models\",\n      \"journal\": \"Cancer cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1-2 — pharmacologic selectivity profiling with in vivo tumor and hematopoietic phenotypes\",\n      \"pmids\": [\"40068598\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"CDK4 is a serine/threonine kinase that, when bound to D-type cyclins and activated by CAK-mediated Thr172 phosphorylation (facilitated by Cdk7 and regulated by Fkbp5-mediated prolyl isomerization and Hsp90/Cdc37 chaperoning), phosphorylates RB to relieve E2F-mediated transcriptional repression and drive G1-to-S phase transition; CDK4 activity is negatively regulated by INK4 family proteins (p16, p15, p18, p19) competing with D-cyclins and positively modulated by CIP/KIP proteins (p21, p27) that scaffold active complexes; beyond cell cycle control, CDK4 directly phosphorylates GCN5, AMPKα2, FLCN, SPOP, EZH2, and CDC25A to regulate glucose metabolism, fatty acid oxidation, lysosomal/mTORC1 function, PD-L1 stability, and inflammatory signaling, while its transcription is induced by c-MYC; CDK4 R24C mutations found in familial melanoma abolish p16 binding without affecting p21/p27 binding, and CDK4 amplification or CDK6-INK4 complex formation mediates resistance to CDK4/6 inhibitors.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"CDK4 is a cyclin D-dependent serine/threonine kinase that serves as a central integrator of mitogenic signaling, coupling growth factor input to G1/S cell cycle progression, cell size control, and metabolic reprogramming. Upon binding D-type cyclins, CDK4 is activated by Cdk7-mediated T-loop phosphorylation at Thr172—a continuously required modification—and phosphorylates the retinoblastoma protein (Rb) to release E2F transcription factors, cooperating with CDK2 to drive S-phase entry [PMID:23622515, PMID:16678773, PMID:32255427]. CDK4 activity is negatively regulated by INK4 family inhibitors (p16, p18, p19) that compete with D-cyclins for CDK4 binding, by FKBP5-mediated prolyl isomerization at Thr172-Pro173 that blocks activating phosphorylation, and by Hsp90-Cdc37 chaperoning that maintains a storage pool of inactive kinase [PMID:8741839, PMID:30485818, PMID:16949366]. Beyond cell cycle control, CDK4 directly phosphorylates GCN5 to suppress hepatic gluconeogenesis, AMPKα2 to inhibit fatty acid oxidation, FLCN to regulate lysosomal mTORC1 signaling, and CDC25A to control its proteasomal turnover, and CDK4/6 inhibition enhances anti-tumor immunity by inducing endogenous retroviral element expression and suppressing regulatory T cells via DNMT1 [PMID:24870244, PMID:29053957, PMID:31395606, PMID:28192398, PMID:28813415].\",\n  \"teleology\": [\n    {\n      \"year\": 1994,\n      \"claim\": \"Establishing how CDK4 is enzymatically switched on resolved the question of what activates cyclin D-bound CDK4: CAK (p39MO15/cyclin H) phosphorylates Thr172 constitutively, showing activation depends on cyclin D availability rather than CAK regulation.\",\n      \"evidence\": \"In vitro kinase assays with recombinant proteins and immunodepletion of CAK across cell cycle stages\",\n      \"pmids\": [\"7935441\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Thr172 phosphorylation is continuously required or a one-time event was not resolved\", \"Identity of the metazoan CAK subunit acting on CDK4 in vivo was not confirmed\"]\n    },\n    {\n      \"year\": 1996,\n      \"claim\": \"Defining the INK4 inhibitory mechanism showed that p19INK4d and p18INK4c bind CDK4/6 in a manner mutually exclusive with D-type cyclins, establishing the competition model for CDK4 regulation and explaining how INK4 accumulation during differentiation extinguishes CDK4 activity.\",\n      \"evidence\": \"Competitive binding assays with recombinant proteins and co-immunoprecipitation during myogenic differentiation time courses\",\n      \"pmids\": [\"8741839\", \"8898364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for mutual exclusivity of INK4 and cyclin D binding was not yet available\", \"Whether INK4-CDK4 complexes serve functions beyond inhibition was unknown\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Discovery that SEI-1 renders cyclin D1-CDK4 resistant to p16INK4a inhibition revealed an unexpected positive regulatory layer, showing that CDK4 activity can be maintained even under high INK4 pressure during growth factor stimulation.\",\n      \"evidence\": \"Protein binding assays, CDK4 kinase activity rescue in the presence of p16, ectopic expression in fibroblasts\",\n      \"pmids\": [\"10580009\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for how SEI-1 overcomes INK4 inhibition was not defined\", \"Whether SEI-1 regulation occurs in all cell types was not tested\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"Identifying c-MYC as a direct transcriptional activator of the CDK4 promoter connected oncogenic MYC signaling to CDK4 upregulation, establishing a proliferative transcription–kinase relay.\",\n      \"evidence\": \"Promoter-reporter assays with E-box mutations, c-MYC null cells with CDK4 rescue\",\n      \"pmids\": [\"10688915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other transcription factors cooperate with MYC at the CDK4 promoter was not addressed\", \"Contribution of MYC-driven CDK4 vs other MYC targets to proliferative rescue was not quantified\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"The CDK4-R24C knock-in melanoma model demonstrated that loss of p16INK4a-mediated CDK4 inhibition is sufficient to drive melanoma susceptibility in vivo, directly linking the germline familial melanoma mutation to the p16-CDK4-Rb tumor-suppressive axis.\",\n      \"evidence\": \"Knock-in mice with CDK4-R24C, carcinogen treatment, compound mutant analysis with INK4 family members\",\n      \"pmids\": [\"11606789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CDK4-R24C affects substrates beyond Rb was not examined\", \"Human genetic penetrance modifiers were not modeled\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Two advances resolved CDK4's structural chaperone requirements and its functional redundancy with CDK2: the Hsp90-Cdc37-CDK4 ternary complex structure showed how chaperone scaffolding stabilizes CDK4, while Cdk2/Cdk4 double-knockout mice proved that these kinases cooperatively phosphorylate Rb in vivo with E7-mediated Rb inactivation rescuing double-KO lethality.\",\n      \"evidence\": \"Single-particle EM of reconstituted Hsp90-Cdc37-CDK4 complex; double-knockout mouse embryos with epistasis rescue by HPV-E7\",\n      \"pmids\": [\"16949366\", \"16678773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Atomic-resolution structure of CDK4 within the chaperone complex was lacking\", \"Which specific Rb phospho-sites are CDK4- vs CDK2-dependent in vivo was undefined\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Chemical-genetic dissection of Cdk7 as the metazoan CDK4 activating kinase revealed that, unlike CDK1/CDK2, CDK4 requires continuous T-loop phosphorylation by Cdk7, establishing an activation cascade during G1 re-entry.\",\n      \"evidence\": \"Analog-sensitive Cdk7 allele inhibition, in vitro kinase assays, phospho-specific antibodies during quiescence exit\",\n      \"pmids\": [\"23622515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Why CDK4 T-loop phosphorylation is labile compared to CDK2 was not structurally explained\", \"Whether other kinases can substitute for Cdk7 in specific tissues was not tested\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Identification of GCN5 as a direct CDK4 substrate in hepatocytes established a cell-cycle-independent metabolic function: cyclin D1-CDK4 phosphorylates GCN5, increasing PGC-1α acetylation to suppress gluconeogenesis, with hepatic cyclin D1 loss causing hyperglycemia.\",\n      \"evidence\": \"In vitro kinase assay on GCN5, liver-specific conditional knockout, glucose tolerance tests in mice\",\n      \"pmids\": [\"24870244\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full spectrum of CDK4 phosphorylation sites on GCN5 was not mapped\", \"Whether CDK6 compensates in liver was not addressed\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Three discoveries expanded CDK4's substrate repertoire and immune-regulatory functions: CDK4 directly phosphorylates AMPKα2 to suppress fatty acid oxidation, phosphorylates CDC25A to promote its βTrCP-mediated degradation as a G1/S feedback, and CDK4/6 inhibition stimulates endogenous retroviral element expression and suppresses Tregs via DNMT1 to enhance anti-tumor immunity.\",\n      \"evidence\": \"In vitro kinase assays with mutagenesis and knockout epistasis for AMPKα2 and CDC25A; transcriptomics, dsRNA quantification, and immune cell profiling in mouse models and clinical biopsies for immune effects\",\n      \"pmids\": [\"29053957\", \"28192398\", \"28813415\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether AMPKα2 phosphorylation is cell-cycle-phase-specific was not resolved\", \"Direct CDK4 vs CDK6 contribution to immune phenotypes was not genetically separated\", \"CDC25A phosphorylation site specificity for CDK4 vs CDK6 was not distinguished\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"The discovery that FKBP5 catalyzes cis-trans isomerization of CDK4's Thr172-Pro173 bond to inhibit activating phosphorylation, and sequesters CDK4 in the Hsp90 complex, revealed a novel prolyl-isomerase-dependent checkpoint on CDK4 activation during differentiation.\",\n      \"evidence\": \"In vitro isomerization assay, phospho-Thr172 blotting, Fkbp5 knockout mouse muscle regeneration\",\n      \"pmids\": [\"30485818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FKBP5 regulation of CDK4 operates outside muscle lineage was not tested\", \"Structural basis for FKBP5 selectivity for CDK4 over CDK6 was not defined\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"Two studies defined the physical basis for CDK4/6 inhibitor resistance: INK4 proteins (p16INK4a) bound to CDK4 physically occlude palbociclib engagement, and FLCN was identified as a direct CDK4 substrate linking CDK4 to lysosomal mTORC1 regulation and autophagic flux.\",\n      \"evidence\": \"Chemo-proteomics with isogenic CDKN2A lines for drug-target engagement; in vitro CDK4 kinase assay on FLCN with lysosomal fractionation and autophagy assays\",\n      \"pmids\": [\"30837298\", \"31395606\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether FLCN phosphorylation is the primary mechanism linking CDK4 to mTORC1 or one of several was not resolved\", \"Whether INK4-mediated drug occlusion applies equally to all CDK4/6 inhibitor chemotypes was not tested\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Live single-cell imaging of CDK4/6 activity showed it rises before CDK2 in G1 and acts as a stress-responsive gatekeeper: CDK4/6 inactivation can return cells to quiescence early in G1 but this capacity diminishes as S phase approaches; separately, CDK4 phosphorylates EZH2 to activate STAT3-mediated proinflammatory signaling in keratinocytes relevant to psoriasis.\",\n      \"evidence\": \"Fluorescent CDK4/6 and CDK2 activity reporters in living cells with stress perturbation; genetic and pharmacological pathway dissection of CDK4→EZH2→STAT3→IκBζ in psoriasis mouse models\",\n      \"pmids\": [\"32255427\", \"32701505\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Direct in vitro CDK4 kinase assay on EZH2 was not explicitly shown\", \"Molecular determinants that make CDK4/6 activity labile to stress were not identified\", \"Whether CDK4-EZH2 axis operates in non-keratinocyte inflammatory contexts was not tested\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CDK4's role in cell size control was established: CDK4 sets the size threshold for G1/S by opposing p38 MAPK-mediated growth restriction, functioning analogously to a size thermostat; additionally, INK4 ternary complexes with cyclin D-CDK6 were shown to confer CDK4/6 inhibitor resistance while preserving ATP binding.\",\n      \"evidence\": \"CDK4 inhibitor/overexpression with p38 reporter and cell size measurements; in vitro binding and kinase assays with INK4C-cyclin D-CDK6 complexes, breast cancer genomic survey\",\n      \"pmids\": [\"34022133\", \"34544752\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Whether CDK4 directly phosphorylates a size-sensing substrate is unknown\", \"Whether the INK4 ternary complex resistance mechanism applies to next-generation CDK4-selective inhibitors was not tested\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Downstream fate of CDK4-phosphorylated Rb was clarified: TRIM28 ubiquitinates phospho-Rb for proteasomal degradation, while SETDB1's Tudor domain protects phospho-Rb from TRIM28, adding a post-phosphorylation stability layer to CDK4-Rb signaling.\",\n      \"evidence\": \"Co-immunoprecipitation, ubiquitination assays, SETDB1 Tudor domain mutants, CDK4/6 inhibitor rescue\",\n      \"pmids\": [\"36637424\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CDK4-specific vs CDK2-specific Rb phospho-marks differentially recruit TRIM28 was not tested\", \"Physiological contexts where SETDB1 protection is rate-limiting for Rb levels are unknown\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Tissue-specific CDK4 vs CDK6 dependency was resolved: HR+ breast cancer cells depend predominantly on CDK4 while hematopoietic cells rely on CDK6, enabling CDK4-selective inhibitors to achieve deeper antitumor responses with reduced neutropenia.\",\n      \"evidence\": \"Selective CDK4 inhibitor (atirmociclib) testing in mouse models, bone marrow cell assays, dose-intensification studies\",\n      \"pmids\": [\"40068598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular basis for CDK4 vs CDK6 tissue preference is not mechanistically defined\", \"Whether CDK4-selective inhibition spares all CDK6-dependent lineages long-term was not fully characterized\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Key unresolved questions include the structural basis for CDK4's continuous requirement for T-loop phosphorylation (unlike CDK2), the full phosphoproteome of CDK4 vs CDK6 across tissues, and the molecular determinants that specify CDK4 vs CDK6 tissue dependency.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Low\",\n      \"gaps\": [\"No high-resolution structure of active cyclin D-CDK4 with a physiological substrate\", \"Complete CDK4 vs CDK6 substrate specificity has not been systematically mapped\", \"How CDK4 metabolic functions are coordinated with cell cycle functions in the same cell is unknown\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 2, 8, 10, 11, 12, 22]},\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [3, 23]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [6, 9, 15]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [0, 13]},\n      {\"term_id\": \"GO:0005764\", \"supporting_discovery_ids\": [12]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [1, 2, 4, 5, 6, 11, 19, 23]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [7, 9, 15, 22]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [8, 10]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [21]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [14, 16, 17, 25]}\n    ],\n    \"complexes\": [\n      \"Cyclin D1-CDK4\",\n      \"Cyclin D3-CDK4\",\n      \"Hsp90-Cdc37-CDK4\"\n    ],\n    \"partners\": [\n      \"CCND1\",\n      \"CCND3\",\n      \"CDC37\",\n      \"HSP90AA1\",\n      \"CDKN2A\",\n      \"CDKN2C\",\n      \"CDKN2D\",\n      \"FKBP5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```\n\n--- ROUND 2 (R2/R3, augmented corpus) ---\n\n```json\n{\n  \"mechanistic_narrative\": \"CDK4 is a D-type cyclin-dependent serine/threonine kinase that functions as a master regulator of the G1-to-S phase cell cycle transition and integrates mitogenic, metabolic, and immune-regulatory signals. Upon binding D-type cyclins (assembled with the aid of CIP/KIP scaffold proteins p21/p27), CDK4 is activated by CAK/Cdk7-mediated phosphorylation of Thr172 and sequentially phosphorylates Rb to displace HDAC, relieve E2F-mediated transcriptional repression, and commit cells to S-phase entry; this activation is negatively regulated by INK4 family inhibitors (p16, p15, p18, p19) that compete with D-cyclins for CDK4 binding, modulated by Hsp90/Cdc37 chaperoning and Fkbp5-mediated prolyl isomerization of the T-loop [PMID:8449399, PMID:7935441, PMID:10499802, PMID:23622515, PMID:30485818]. Beyond Rb, CDK4 directly phosphorylates GCN5 to suppress hepatic gluconeogenesis, AMPKα2 to inhibit fatty acid oxidation, FLCN to regulate lysosomal mTORC1 recruitment, SPOP to stabilize PD-L1, EZH2 to activate STAT3-driven inflammatory gene expression, and CDC25A to generate a G1/S negative-feedback loop [PMID:24870244, PMID:29053957, PMID:31395606, PMID:29160310, PMID:32701505, PMID:28192398]. Germline CDK4 R24C mutations that abolish p16 binding cause familial melanoma susceptibility [PMID:8528263, PMID:7652577].\",\n  \"teleology\": [\n    {\n      \"year\": 1993,\n      \"claim\": \"The identification of p16INK4a as a direct CDK4 inhibitor and the reconstitution of CDK4/cyclin D-dependent Rb phosphorylation established the core p16–CDK4/cyclin D–Rb–E2F pathway governing G1/S progression.\",\n      \"evidence\": \"In vitro kinase inhibition assays, baculovirus/Sf9 reconstitution of CDK4/cyclin D complexes, E2F release assays, co-IP in normal vs. SV40-transformed fibroblasts\",\n      \"pmids\": [\"8259215\", \"8449399\", \"8101826\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Mechanism of CDK4 enzymatic activation (activating kinase) unknown at this stage\", \"Stoichiometry and competition between p16 and cyclins for CDK4 binding not yet defined\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"Discovery that CAK (Cdk7/cyclin H) phosphorylates CDK4 on Thr172 for activation, and that CIP/KIP proteins promote CDK4/cyclin D assembly and nuclear targeting, resolved how CDK4 is activated and how its complexes are assembled in a regulated manner.\",\n      \"evidence\": \"In vitro reconstitution with p39MO15/cyclin H, immune-depletion, quantitative assembly kinetics, subcellular fractionation\",\n      \"pmids\": [\"7935441\", \"9106657\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Cdk7 is the sole CDK4-activating kinase in vivo was not established\", \"CIP/KIP titration model (assembly vs. inhibition) not fully resolved\"]\n    },\n    {\n      \"year\": 1994,\n      \"claim\": \"The expansion of the INK4 family (p15INK4B, p18INK4C, p19INK4D) revealed that CDK4/6 activity is controlled by a family of structurally related competitive inhibitors, some induced by extracellular signals like TGF-β.\",\n      \"evidence\": \"cDNA isolation, yeast two-hybrid, kinase inhibition assays, TGF-β induction in keratinocytes, retroviral overexpression and cell cycle analysis\",\n      \"pmids\": [\"8078588\", \"8001816\", \"7739547\", \"8741839\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Relative contribution of individual INK4 members in specific tissues not yet determined\", \"Structural basis for INK4–CDK4 competition with cyclins not resolved\"]\n    },\n    {\n      \"year\": 1995,\n      \"claim\": \"The CDK4 R24C mutation in melanoma and its confirmation as a familial melanoma susceptibility allele demonstrated that p16-CDK4 binding is a critical tumor-suppressor axis in human cancer.\",\n      \"evidence\": \"Mutation sequencing from melanoma tissue and familial kindreds, p16/p21/p27 binding assays, CTL recognition assay\",\n      \"pmids\": [\"7652577\", \"8528263\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether R24C alters CDK4 kinase activity per se or only p16 binding was not fully dissected\", \"Tissue specificity of melanoma susceptibility not mechanistically explained\"]\n    },\n    {\n      \"year\": 1999,\n      \"claim\": \"Mechanistic dissection of ordered Rb inactivation showed that CDK4/6 first phosphorylates the Rb C-terminus to displace HDAC, while CDK2 subsequently disrupts the pocket domain to release E2F, establishing a two-step Rb inactivation model.\",\n      \"evidence\": \"In vitro phosphorylation with defined Rb mutants, HDAC binding assays, co-immunoprecipitation\",\n      \"pmids\": [\"10499802\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether this ordered phosphorylation sequence operates identically in all cell types was untested\", \"Full complement of CDK4-specific Rb phosphorylation sites not mapped\"]\n    },\n    {\n      \"year\": 2000,\n      \"claim\": \"The discovery that c-MYC transcriptionally activates CDK4 placed CDK4 downstream of a major oncogenic transcription factor, integrating mitogenic signaling with cell cycle kinase expression.\",\n      \"evidence\": \"SAGE, promoter binding assay, ectopic CDK4 rescue of c-MYC-deficient RAT1 cells\",\n      \"pmids\": [\"10688915\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether MYC-dependent CDK4 induction is rate-limiting for proliferation in most contexts was unclear\"]\n    },\n    {\n      \"year\": 2001,\n      \"claim\": \"CDK4 R24C knock-in mice confirmed that INK4-insensitive CDK4 is sufficient to initiate melanoma in vivo, and genetic epistasis established a hierarchy among INK4 family members (p18 > p15) in melanocyte tumor suppression.\",\n      \"evidence\": \"Knock-in mouse model, carcinogen treatment, tumor sequencing, genetic crosses with INK4 knockouts\",\n      \"pmids\": [\"11606789\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular mechanism of melanocyte-specific CDK4 dependency not resolved\", \"Contribution of CDK6 in this tissue not assessed\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Structural and genetic studies revealed that Hsp90/Cdc37 chaperone CDK4 as a ternary complex, and that combined CDK4/CDK2 loss causes embryonic lethality due to Rb hypo-phosphorylation, confirming CDK4 cooperates with CDK2 to inactivate Rb in vivo.\",\n      \"evidence\": \"Single-particle EM of Hsp90-Cdc37-Cdk4, double knockout mice, HPV-E7 rescue experiments\",\n      \"pmids\": [\"16949366\", \"16678773\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How Cdc37 specifically recognizes CDK4 over other kinases remained unclear\", \"Tissue-specific requirements for CDK4 vs. CDK2 not fully delineated\"]\n    },\n    {\n      \"year\": 2013,\n      \"claim\": \"Chemical genetic proof that Cdk7 is the physiological CDK4-activating kinase, required to maintain (not just establish) CDK4 activity during G1 exit, defined the upstream CDK activation cascade.\",\n      \"evidence\": \"Analog-sensitive Cdk7 allele, in vitro Cdk4 activation, cell quiescence/exit phosphorylation time course\",\n      \"pmids\": [\"23622515\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether Cdk7 regulation of CDK4 vs. CDK6 differs quantitatively was not resolved\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"CDK4 was shown to directly phosphorylate GCN5, suppressing hepatic gluconeogenesis independently of cell cycle control, establishing CDK4 as a metabolic kinase linking insulin/amino acid signaling to glucose homeostasis.\",\n      \"evidence\": \"In vitro CDK4 kinase assay on GCN5, PGC-1α acetylation, Cdk4−/− mouse metabolic phenotype, CDK4 inhibitor treatment\",\n      \"pmids\": [\"24870244\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Full spectrum of CDK4 metabolic substrates not catalogued\", \"Relative contributions of CDK4 vs. CDK6 to hepatic metabolism unclear\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"A burst of discoveries identified multiple non-Rb CDK4 substrates (AMPKα2, SPOP, CDC25A) and revealed CDK4/6 inhibitors stimulate anti-tumor immunity by activating endogenous retroviruses, linking CDK4 kinase activity to fatty acid oxidation, PD-L1 stability, G1/S feedback, and immune surveillance.\",\n      \"evidence\": \"In vitro kinase assays on AMPKα2/SPOP/CDC25A, Cdk4−/− mouse exercise phenotype, AMPK epistasis, ubiquitination reconstitution, tumor-infiltrating lymphocyte analysis, dsRNA/IFN measurement in preclinical models and clinical biopsies\",\n      \"pmids\": [\"29053957\", \"29160310\", \"28192398\", \"28813415\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis for CDK4 recognition of diverse non-Rb substrates unknown\", \"Whether SPOP phosphorylation occurs at physiological CDK4 activity levels in all tumor types not established\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Fkbp5 was identified as a CDK4-specific regulator that both sequesters CDK4 within Hsp90 complexes and inhibits Thr172 phosphorylation through prolyl isomerization, providing a novel conformational gating mechanism for CDK4 activation during myogenic differentiation.\",\n      \"evidence\": \"Prolyl isomerase assay, Thr172 phosphorylation analysis, Fkbp5−/− mouse muscle regeneration\",\n      \"pmids\": [\"30485818\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether other prolyl isomerases similarly regulate CDK4 is unknown\", \"Generalizability beyond muscle differentiation not tested\"]\n    },\n    {\n      \"year\": 2019,\n      \"claim\": \"CDK4 was shown to phosphorylate FLCN to regulate lysosomal mTORC1 recruitment in response to amino acids, extending CDK4's metabolic functions to nutrient-sensing and lysosomal biology, while chemo-proteomics revealed that high p16/CDKN2A levels prevent palbociclib engagement of CDK4.\",\n      \"evidence\": \"In vitro CDK4 kinase assay on FLCN, lysosomal function assays, mTORC1 imaging, chemo-proteomics target engagement in isogenic CDKN2A cell lines\",\n      \"pmids\": [\"31395606\", \"30837298\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether CDK4-FLCN axis operates independently of Rb phosphorylation in all contexts unclear\", \"No crystal structure of CDK4-FLCN complex\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Live single-cell imaging established that CDK4/6 activity rises before CDK2 activity during cell cycle entry and that stress signals can rapidly inactivate CDK4/6 to return cells to quiescence, positioning CDK4/6 as the primary G1 activity sensor determining quiescence exit.\",\n      \"evidence\": \"Single-cell CDK4/6 and CDK2 live-cell activity reporters, stress perturbation experiments\",\n      \"pmids\": [\"32255427\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Molecular identity of stress signals that inactivate CDK4/6 not fully defined\", \"Whether CDK4 and CDK6 contribute equally in this reporter system is unresolved\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"CDK6 upregulation was shown to confer CDK4/6 inhibitor resistance through formation of p18INK4C-cyclin D-CDK6 ternary complexes that occlude drug binding while retaining kinase activity, explaining a major clinical resistance mechanism and motivating selective CDK4 inhibitor development.\",\n      \"evidence\": \"In vitro binding/kinase assays, chemo-proteomics, physical modeling, PROTAC degrader validation in vivo\",\n      \"pmids\": [\"34544752\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether resistance-conferring ternary complexes form in all tumor contexts untested\", \"Structural details of drug occlusion at atomic resolution lacking\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Selective CDK4 inhibition demonstrated that CDK4 is dispensable for hematopoiesis (CDK6-dependent) while essential for HR+ breast cancer cell proliferation, establishing a therapeutic window for selective CDK4 targeting with reduced neutropenia.\",\n      \"evidence\": \"Selective CDK4 inhibitor profiling, neutrophil toxicity assays, CDK4 vs. CDK6 selectivity, HR+ breast cancer models\",\n      \"pmids\": [\"40068598\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Long-term resistance mechanisms to selective CDK4 inhibitors not characterized\", \"Whether selective CDK4 inhibition preserves the immune-stimulatory effects of dual CDK4/6 inhibition is unknown\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"Outstanding questions include the structural basis for CDK4 substrate recognition across its diverse non-Rb targets, the extent to which CDK4 metabolic and immune functions are Rb-independent, and how CDK4 and CDK6 are differentially deployed across tissues and tumor types.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No high-resolution structure of CDK4 bound to non-Rb substrates\", \"Rb-independent vs. Rb-dependent contributions of CDK4 not systematically dissected\", \"Tissue-specific CDK4 vs. CDK6 functional partitioning incompletely mapped\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0140096\", \"supporting_discovery_ids\": [1, 3, 17, 27, 29, 30, 33, 34, 36]},\n      {\"term_id\": \"GO:0016740\", \"supporting_discovery_ids\": [1, 3, 27, 29, 30, 33, 34, 36]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005634\", \"supporting_discovery_ids\": [4, 22]},\n      {\"term_id\": \"GO:0005829\", \"supporting_discovery_ids\": [4, 20]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [0, 1, 3, 4, 17, 21, 25, 33, 38]},\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [23, 29, 34, 36, 39]},\n      {\"term_id\": \"R-HSA-1430728\", \"supporting_discovery_ids\": [27, 29]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [9, 14, 19, 40, 42]},\n      {\"term_id\": \"R-HSA-168256\", \"supporting_discovery_ids\": [30, 31]}\n    ],\n    \"complexes\": [\n      \"Cyclin D1-CDK4\",\n      \"Cyclin D2-CDK4\",\n      \"Cyclin D3-CDK4\",\n      \"Hsp90-Cdc37-CDK4\"\n    ],\n    \"partners\": [\n      \"CCND1\",\n      \"CCND2\",\n      \"CCND3\",\n      \"CDKN2A\",\n      \"CDKN1A\",\n      \"CDKN1B\",\n      \"CDC37\",\n      \"FKBP5\"\n    ],\n    \"other_free_text\": []\n  }\n}\n```"}